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GENERAL INTRODUCTION 
Phosphorylase Kinase 
General properties of phosphorylase kinase 
Phosphorylase kinase plays a key regulatory role in glycogen metabohsm 
by catalyzing the phosphorylation of glycogen phosphorylase, which converts 
phosphorylase b, inactive, to phosphorylase a, active. Phosphorylase a, in turn, 
facilitates the breakdown of glycogen to glucose-l-phosphate. Krebs and Fischer 
first isolated phosphorylase kinase firom rabbit skeletal muscle (1). Although 
phosphorylase kinase was the first protein kinase known to modulate another 
enzyme's activity by phosphorylation (2), there are many unknowns regarding 
the structure, function, and regulation of phosphorylase kinase. This incomplete 
knowledge can be related to the complexity of phosphorylase kinase, in its 
regulation and its structure. This enzyme is found in several tissues, including 
smooth muscle, Hver, heart, brain (3-6). The rabbit skeletal muscle form is the 
best characterized form. 
Two major pathways exist for the regulation of glycogenolysis involving 
phosphorylase kinase (7,8). The first pathway is hormonal stimidation in the 
presence of epinephrine or glucagon. Rising levels of epinephrine result in 
increased levels of cyclic AMP which in tvim initiates the activation of cycUc 
AMP-dependent protein kinase (protein kinase A). Protein kinase A 
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phosphoiylates the a and P subunits of phosphorylase kinase yielding activated 
phosphorylase kinase. The second pathway involves neuronal and a-adrenergic 
hormonal control of glycogenolysis. These systems are coordinated by calcium, 
which is believed to serve as a mediator to link glycogenolysis with muscle 
contraction (9-12). Calcium binds to the 5 sub unit of phosphorylase kinase and 
stimulates calcium dependent activity. Additionally, exogenous calcium-
calmodulin binds to calmodulin binding sites on the a and P subvmits resulting 
in activation. 
Phosphorylase kinase is a very large and complex enzyme. The enzyme 
is a hexadecamer with subunit composition of (a,3,7,8)4 and a molecular 
weight of 1.3 x 10® kDa (8,13). The a, Mr 138 kDa, and p, Mr 125 kDa are 
regulatory subunits that can be phosphorylated and can bind exogenous 
calmodulin (14-17). Both events affect phosphorylase kinase activity (8,13). 
Two isozymes of phosphorylase kinase have been isolated from white, fast-
twitch, and red, slow twitch, muscles (18,19). These isozymes differ in the 
size of the a subunit, a and a'. The difference in physiological function among 
these isozymes is not clear. The y subimit, Mr 45 kDa, is the catalytic 
subunit (20-22). The 5 subunit, Mr 17 kDa, is almost identical to bovine 
brain calmodulin and confers calcium sensitivity to the enzyme (23,24). 
Phosphorylase kinase is distinct from many other calmodulin-regxUated 
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systems, in that tight binding of the 5 subunit occurs in the absence of 
calcium (25). 
Roles of subunits 
a and the regulatory subunits 
The a and P subunits of phosphorylase kinase are regvilatory subunits. 
Sequence comparisons reveal that a and P are homologous (15). Some 
sequence differences exist, the N-terminus of P contains an unique sequence, 
and the middle of a has two unique sequences, with respect to the P subimit 
(15). The primary structures of a and P both contain a prenylation signal. 
Prenylation of a and P has been verified and both proteins are farnesylated. 
However, a and P £ire not additionally processed, like many other prenylated 
proteins (26). 
Activation of holoenzyme residts fi:om phosphorylation of a and P by 
protein kinase A (8,13) or by Ca^^-dependent autophosphorylation (27,28). 
Protein kinase A catalyzed activation of phosphorylase kinase residts firom 
phosphorylation of the p subunit. Once a minimum of 1 mole phosphate/ 
(aPyS) hexadecamer has been incorporated into the P subunit, 
phosphorylation of the a subunit can occxir (13). Phosphorylation of p is 
essential for activation and is independent of the phosphorylation level of a 
(29). Phosphorylation of a does not activate phosphorylase kinase (13,29-31). 
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However, phosphorylation of a might be important in sustaining the 
activation level of phosphorylase kinase (8,29,32,33). If the metal ions Ca^^ 
and Mg2+ are present in addition to ATP, phosphorylase kinase can 
autophosphorylate and autoactivate. Multiple sites on the a and P subunits 
are phosphorylated (28,34,35). This autophosphorylation is an 
intramolecular phosphorylation (36,37). The similarity in the mechanism of 
activation, between autophosphorylation and phosphorylation by protein 
kinase A, is revealed in the fact that the same site in the (3 subunit is 
modified (38). 
The a and P subunits contain calmodulin binding sites. Binding of 
Ca^^-calmodulin to a and |3 (39) activates phosphorylase kinase (30,40 
178,41). The binding of exogenous calmodulin, termed 5', to a and P is Ca^-^-
dependent, as it can be inhibited by trifluoperazine, and calmodulin binding 
peptides melittin and mastoparan (42). Protein kinase A and calmodulin 
complement each other in the regvilation of phosphorylase kinase activity (43). 
Calmodulin binding to P can block phosphorylation by protein kinase A. 
Phosphorylation of P by protein kinase A can block calmodulin binding, a and 
P have several proposed calmodulin binding sites based on comparison of 
their primary structures with other calmodulin binding sequences (14,15). 
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Phosphorylase kinase can be activated upon treatment with 1.8 M 
lithium bromide, which dissociates the holoenzjone into small active 
complexes (21). Renatured ct/p mixtures can inhibit the activity of renatured 
isolated y (44). Isolated or synthetic peptides of P, containing the proposed 
calmodulin binding site, can inhibit phosphorylase kinase (45,46). This 
inhibitory effect of ot/p and P inhibitory peptides is reheved by 
phosphorylation and calmodulin binding. Thus, a and P subunits may be 
involved in the negative regidation of the phosphotransferase activity of 
phosphorylase kinase by directly affecting the conformation, and/or activity of 
the Y subunit (44,46,47). 
The catalytic ysubunit 
Research in the early to mid I980's by Skuster et al. (20), Chan and 
Graves (21,48,49), Kee and Graves (22,50) demonstrated that the y subunit is 
the catalytic subunit of phosphorylase kinase. Two active complexes, ay6 and 
y5, were isolated and purified after treating holoenzyme with lithium 
bromide (21). Both complexes exhibited activity similar to that of 
holoenzyme. Additionally, renatured HPLC purified y subunit contained 
phosphorylase kinase activity (22,50). Kinetic analysis of the renatured y 
subunit showed that the Km values for phosphorylase b and ATP were similar 
to the values obtained with holoenzyme (50). 
6 
The N-terminal region of y, residues 1-276, has homology to the 
catalj^c domain of other protein kinases. Primary sequence alignment 
results in 40% homology (51). The C-terminal region of y, residues 276-386, 
contains two non-contiguous high affinity calmodulin binding domains. 
PhKl3, residues 302-326, and PhK5, residues 342-366 (52,53). The full-
length y subvmit (1-386) has been expressed in E. coli and insect cells by our 
laboratory and others (54-56). Unfortunately, purification of full-length y has 
been difficult. As a result, most work has been done utilizing a truncated 
form of y, residues 1-300, that can be expressed, purified, and renatured from 
inclusion bodies (54). The crystal structure of a truncated form of y, residues 
1-298, has been solved in the presence of Mn^^ and the non-hydrolyzable ATP 
analog, |3-y-imidoadenosine 5' triphosphate (AMP-PNP) (57). The structure of 
the catalytic domain of y is structurally similar to the crystal structure of 
protein kinase A. No structural information is available on the C-terminal 
region containing the calmodulin and autoinhibitory binding segments. 
The 5 subunit 
The 5 subvmit was not identified xmtil 1978, due primarily to its poor 
staining with Coomassie blue after gel electrophoresis (58). It is identical to 
bovine uterus calmodulin (17) and differs firom bovine brain calmodulin by 
two amino acids (13). Calmodulin is a calcium binding protein that mediates 
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control of a variety of enzjones in response to the physiological flux of calcium. 
The 5 subunit acts as a built in sensor for calcium and is responsible for 
conferring calcium sensitivity to phosphorylase kinase. Muscle phosphorylase 
kinase requires calcium for activity. Holoenzjnne phosphorylase kinase 
appears to bind calcium solely through the 5 subxanit (23,24). Tight binding of 
the 5 subunit to phosphorylase kinase occurs in the absence of calcium, 
making this interaction in phosphorylase kinase unique among calmodulin 
regulated enzymes (16,25). 
Catalytic properties 
Nonactivated phosphorylase kinase exhibits little activity at 
physiological pH, yet has considerable activity at higher pH (27). This pH 
dependency changes upon activation by phosphorylation, calmodulin binding, 
proteolysis, and dissociation into aY6 and yd complexes (59). The 
nonactivated enzyme has a ratio of activity, pH 6.8 compared to pH 8.2, of 
0.04-0.08, whereas the activated enzyme has a ratio of 0.3-1.0 (59). This 
difference in pH dependency suggests that a functional group located in the 
active site region important for catalysis may be affected by the state of 
activation. It has been proposed that a catalytic base helping pidl a proton 
from a reactive seryl residue of substrate during catalysis could explain the 
high tiunover rate of serine/threonine kinases (60,61). 
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Phosphorylase kinase requires Mg2+ to form active substrate with ATP, 
for phosphotransferase activity. Excess over that required to form 
MgATP2-, stimulates phosphorylase kinase activity (62). This stimulation 
effect of free Mg2+ can be observed via a decrease in Km for phosphorylase b 
and ATP, as well as, an increase in Vmax (63). Mn^-^, on the other hand, will 
activate phosphorylase kinase at low concentrations and inhibit 
phosphorylase kinase at high concentrations (50). 
Substrate specificity 
The phosphorylation of phosphorylase b by phosphorylase kinase is a 
highly specific reaction. No other protein kinase is known to catalyze this 
reaction. Phosphorylase kinase can phosphorylate other proteins, including 
itself, troponin I, glycogen synthase, neuromodulin, and neurogranin (64). 
However, only the phosphorylation of phosphorylase b has been shown to be 
physiologically relevant. More recently, phosphorylase kinase was shown to 
exhibit dual-specificity by the demonstration of angiotensin II tyrosine 
phosphorylation. Mn2+ activates this tyrosine kinase activity of 
phosphorylase kinase (65). Phosphorylase kinase catalyzes the formation of 
phosphorylase a by phosphorylation of serine 14 in glycogen phosphorylase b 
(66). Peptides of the phosphorylatable region of phosphorylase b are effective 
substrates of phosphorylase kinase (67). A phosphorylation study on a series 
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of sjnithetic peptide derivatives based on the phosphorylatable region, 
^KHKQIS^'^VRGLis, revealed that 1) a basic amino acid is required N-
terminal (P-3), 2) a basic amino acid is preferred, but not required, C-
terminal (P+2) to the phosphorylatable serine, 3) threonine can not replace 
serine as an acceptor, 4) hydrophobic amino acids are preferred on either side 
of serine, at P-1 and P+1 (67-69). 
An alternative approach to help define substrate interactions is to use 
mutants of the truncated y (1-300) with various peptide substrates. This 
approach was utilized via charge-reversal mutations to define the P-3 binding 
site in 7(1-300) as residue El 10 (70). Crystallographic results with protein 
kinase A suggested that E127 of protein kinase A interacted with an arginine 
residue in the P-3 of its substrates (71-73). Mutation of this conserved 
glutamate residue, EllOK, in trxmcated 7(1-300) combined with the charge-
reversal in peptide substrate, KREQISVRGL, led to the identification of an 
electrostatic interaction between these two residues. Recent results from X-
ray crystallography of truncated 7(1-298) containing a peptide substrate, MC-
peptide RQMSFRL, confirms this El 10 interaction (74). 
Additional important information on substrate specificity has been 
obtained through the use of peptide libraries. For truncated 7(1-300), the 
sequence, KRMMSFFL, was favored for optimal interactions (75). However, 
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no kinetic analysis was performed with this peptide substrate. A modified 
version of this peptide, termed MC-peptide, was analyzed in the 
crystallographic studies of trxmcated Y(1-298). The MC-peptide was found to 
be a better substrate than the peptide derived firom the natural sequence of 
phosphorylase b (74). 
Ca2+/Calmodulin-dependent protein kinases/autoinhibition 
The catalytic activity of many protein kinases appears to be regulated 
by an autoinhibitory mechanism, also known as intrasteric regulation (76,77). 
Many autoinhibitory domains were discovered by the observation that many 
proteolyzed or trxmcated forms of these protein kinases are active. The 
autoinhibitory domain often, but not always resembles the consensus 
sequence of an enzyme's substrate. Protein kinase A was the first described 
case of intrasteric regulation by a pseudosubstrate domain located on the 
regulatory subxmit (78). Substantial evidence exists implicating the 
autoinhibitory mechanism in protein kinase G, protein kinase C, myosin light 
chain kinase, twitchin, calmodulin-dependent protein kinase I and 
phosphorylase kinase (79-82). Phosphorylase kinase is a member of the Ca2+ 
/calmodulin-dependent protein kinase family. Members of the Ca2+ 
/calmodulin-dependent protein kinase family, myosin light chain kinase, 
calmodulin-dependent protein kinases I, II, IV, and phosphorylase kinase 
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contain an autoinhibitory domain, which overlaps the calmodulin binding 
regions (76). A possible mechanism for this intrasteric regxxlation is that the 
autoinhibitory domain occupies the enzyme's active site. Binding of 
calmodulin in the presence of calcium induces a conformational change 
releasing the autoinhibitory domain from the active site, thus activating the 
enzjone. 
As previously mentioned, the crystsd structure of truncated 7(1-298) 
has been solved (57). Knighton et al, modeled myosin hght chain kinase based 
on protein kinase A complexed with the protein kinase inhibitor (PKE) 
peptide. These results indicated that it was theoretically possible for the 
autoinhibitory domain to bind at the active site (83). A truncated form of 
twitchin kinase, containing the kinase catalytic core and the sixty residue C-
terminal autoinhibitory domain was crystallized. Twitchin kinase is related 
to myosin Ught chain kinase. Although twitchin is not activated by 
calmodxilin, it is activated by the calciiun binding protein SlOO, which has 
homology to calmodulin. The crystal structure of twitchin kinase reveals that 
the C-termined autoinhibitory domain extends through the active site making 
extensive contacts with the active site region and passes over the activation 
loop (84). The more recent crystal structure of Ca^+Zcalmodulin-dependent 
protein kinase I illustrates another possibility. In this structiire, the 
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autoinhibitory calmodulin binding C-terminus makes multiple contacts with 
the surface of the large lobe of the catalytic core, but then txims away from the 
activation loop and travels along the small lobe (85). The use of small-angle 
x-ray and neutron scattering resulted in the first structural view of a 
truncated form of skeletal muscle myosin Ught chain kinase complexed with 
calmodulin (86). Calmodulin was near the large lobe of the kinase cataljrtic 
core but away from the catalytic cleft, thus suggesting a major displacement 
of the autoinhibitory domain from the active site. Recently, this structural 
view was expanded via the elucidation of myosin light chain 
kinase/calmodulin complexed with AMP-PNP, and a peptide substrate 
derived from the regulatory light chain, pRLC. This structure illustrates the 
"closed" active conformation of protein kinases. Myosin light chain 
kinase/calmodulin/substrate complex becomes more compact in overall shape. 
The C-terminal autoinhibitory domain, boxmd to calmodulin, actually 
reorients and moves closer to the catalytic domain. New interactions are 
formed between calmodulin and the N-terminus of the kinase (87). 
The regulatory C-terminal domains of the Ca^+Zcalmodulin-dependent 
protein kinase family may be involved in additional functions. The 
autoinhibitory domains of calmodulin-dependent protein kinase II and myosin 
Hght chain kinase have been shown to be crucial for enzymatic stabilization 
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(88) or increased Ca^^/calmodulin-independent activity through 
autophosphorylation (89). Recent work with chimeric forms of smooth and 
skeletal myosin light chain kinases and Ca^+Zcalmodulin-dependent protein 
kinase II suggests that the regulatory C-terminal domains may affect 
substrate recognition and kinase activity (87). 
Protein Phosphatase-1 
General properties 
Protein phosphatase-1, PP-1, plays an equally important, 
complementary regulatory role to phosphorylase kinase in glycogen 
metaboUsm. Protein phosphatase-1 catalyzes the dephosphorylation of 
phosphorylase a. This dephosphorylation converts phosphorylase a, the active 
form, to phosphorylase b, an inactive form. 
Such a phosphorylase a to phosphorylase b converting enzyme was first 
reported by Cori and Green in 1943. They proposed that the removal of AMP 
was responsible for the change fi"om phosphorylase a to phosphorylase b and 
thus named the enzyme PR enzyme, for prosthetic group removing enzyme 
(90). Later PR enzyme was altered to mean phosphorylase rupturing enzyme 
with the discovery that the phosphorylase a to phosphorylase b conversion 
resulted in a halving of the molecular weight (91). In 1959 Krebs, Graves, and 
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Fischer identified PR enzjone as phosphorylase phosphatase, later identified 
as protein phosphatase-1 (92). 
Protein phosphatase-1 is one of four major serine/threonine 
phosphatases, types -1, -2A, 2B, and -2C. These protein phosphatases are 
distinguished via their substrate specificities and susceptibility to specific 
inhibitors (93). Protein phosphatase-1 can be inhibited by Inhibitor 1 and 
Inhibitor 2 and will preferentially dephosphorylate the P subunit of 
phosphorylase kinase. In addition to its role in the regulation of glycogen 
metabohsm, protein phosphatase-1 plays an essential role in other cellular 
processes, such as cell division, muscle contraction, and protein synthesis 
(94). Although protein phosphatase-1 can be found in many different tissues, 
like phosphorylase kinase, the most widely studied form is from rabbit 
skeletal muscle. 
In muscle protein phosphatase-1, PP-IG, is a complex of the catal5^ic 
subunit, Mr 38kDa, with a glycogen binding subunit, Mr 124 kDa (94). 
Protein phosphatase-IG activity and affinity for the glycogen binding subunit 
are regulated by phosphorylation. Phosphorylation of site 1 on the glycogen 
binding subunit, G, by insulin stimulated kinase results in activation of 
protein phosphatase-1 activity. Phosphorylation of site 2 by cAMP-dependent 
protein kinase, (PKA), causes the dissociation of protein phosphatase-1 
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catalytic subiinit, C, from the G subunit. The released protein phosphatase-1 
catalytic subunit can translocate to the cytosol. This results in the inabilitj' 
of protein phosphatase-1 catalytic subunit to dephosphorylate phosphorylase 
a. Phosphorylated Inhibitor 1, phosphorylated by cAMP-dependent protein 
kinase, can bind to protein phosphatase-1 catalytic subunit and inhibit its 
activity. 
Role of subunits 
Diversity in the protein phosphatase family arises from the coupling of 
the catalytic subunit with a variety of non-catalytic targeting or regulatory 
subunits. The catalytic domains of protein phosphatases are highly 
conserved, which suggests similar mechanisms and tertiary structxire (95). 
Thus, structural and functional diversity results from the combination of 
catalytic subunits with their associated non-catalytic targeting or regulatory 
subunits to form heterodimers. In the cell protein phosphatase-1 exists as a 
complex of an isoform of the protein phosphatase catalytic subunit with a 
non-catalytic targeting or regulatory subunit. The non-catalj^ic targeting or 
regulatory subunit influences the activity, substrate specificity and the 
intracellular location of protein phosphatase-1 (94). 
Protein phosphatases type-1, -2A, and -2B catalytic subunits share 
extensive sequence identity and are members of a single gene family (96). 
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The few invariant residues identified are dispersed across the primary 
sequence, with three regions relatively abundant in invariant residues. The 
crystal structures for recombinant protein phosphatase-1 catalytic subunit, 
protein phosphatase 2B holoenzyme and complex with immunosuppressants 
have been solved (85,97-99). The structxires illustrate that the catalytic 
domains of these two phosphatases adopt an identical core structure. The 
carboxyl termini of protein phosphatases are divergent. Evidence suggests 
that these regions may be involved in regulation and substrate specificity 
(95). The regulatory C-tenninus of protein phosphatase-1 catalytic subunit 
would be positioned to interact with residues surrounding the active site and 
restrict the access of substrate (97). 
The targeting or regulatory subunit is the subvmit that directs the 
catalytic subunit to a specific cellular locus. These targeting or regvilatory 
subimits are believed to function by locating the protein phosphatase to a 
particular cellxalar loci in order to be in close proximity to substrate, or to 
sequester the protein phosphatase from substrates and ligands (100). 
Catalj^ic properties 
Protein phosphatases are metalloenzjones. Recombinant protein 
phosphatase-1 requires the addition of Mn2+ (101). The crystal structure of 
protein phosphatase-1 catal3^ic subunit indicates the presence of Fe2+ and 
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Mn2+. Catalysis by serine and threonine protein phosphatases has been 
proposed to occur through a direct attack of an activated water molecule at 
the phosphorous center of substrate, without transfer of phosphate to the 
enzyme (97). This is consistent with kinetic data suggesting that serine and 
threonine protein phosphatases do not form phosphoryl-enzyme 
intermediates (97,102). The catalytic site is located at the base of a shallow 
groove on the surface. Many of the invariant residues occur on intervening 
loops that converge at this site (97). 
Substrate specificity 
Protein phosphatase-1 dephosphorylates the P subunit of 
phosphorylase kinase 10-100 fold faster than the a subxinit of phosphorylase 
kinase (94). Phosphorylase a is the best and most commonly used substrate 
(94). Protein phosphatase-1 does not dephosphorylate phosphopeptide 
substrates weU, even those derived from phosphorylase a (103-105). Failure 
to successfully dephosphorylate phosphopeptide substrates indicates that the 
determinants for recognition of substrate are not only located in the primary 
structure but also in the higher order of substrate. No peptide binding cleft is 
evident from the crystal structxire of protein phosphatase-1 (97). This is 
consistent with the preference of protein phosphatase-1 for intact protein 
substrates and suggests several modes of substrate recognition. The binding 
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of substrate is proposed to occur through interaction of N-tenninal basic 
residues in substrate with acidic residues in the acidic groove, binding of 
phosphoserine to the active site, and interaction of C-terminal residues to the 
hydrophobic groove of protein phosphatase-1 (97). 
Phosphopeptide studies have jdelded some important information on 
protein phosphatase-1 specificity. A preference for basic residues located N-
terminal to the phosphoserine is a general determinant (106). Addtional 
work indicates that a basic residue C-terminal to the phosphoserine might be 
important. Work with phosphorylase phosphatase utilizing peptides derived 
from phosphorylase a by Graves et al in 1960 was the first indication that a 
C-terminal basic residue might be important for specificity (104). 
Modification of the C-terminal basic residue, arginine 16 of phosphorylase by 
nitrosylation, amidation, and more recently through substitution of arginine 
16 to citruUine indicates that in fact, the positive charge present may be 
important for protein phosphatase-1 specificity (105,107). Kinetic analysis of 
the citruUine substituted phosphorylase peptides illustrates the preference 
for arginine 16 for enhanced turnover. Multiple interactions occiu- in 
phosphorylase a that are involved in stabilizing the N-terminal region (108). 
Two dimensional NMR studies indicate an interaction of arginine 16 with the 
phosphoryl group of a peptide substrate (107). The structure of phosphorylase 
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a shows the phosphoserine interacting with arginine 69 and arginine 43'. All 
of these interactions may contribute to the overall structural specificity of 
protein phosphatase-1. 
Mutants of protein phosphatase-1 catalytic subunit have provided 
some information towards understanding the catalysis and substrate 
specificity. Extensive mutagenesis of the acidic groove of protein 
phosphatase-1 resxdted in little effect on the kinetic parameters for 
phosphorylase a (109). These results may be misleading. The acidic groove 
contains multiple acidic residues and the approach of mutating only one 
amino acid at a time may have obscured any changes in interaction with 
phosphorylase a. Mutants of the arginine residue proposed to bind 
phosphosubstrate, R221Q and R221S, exhibit higher Km values for 
phosphorylase a and much lower Vmav values (109,110). Other mutants of 
protein phosphatase-1 have focused mainly on the invariant phosphatase 
residues (110,111). Results in these studies have been consistent with 
identification of the metal binding residues firom the crystal structure. 
Dissertation organization 
The remainder of this dissertation consists of four papers, that will be 
submitted for pubhcation. The first paper addresses the importance of 
arginine 16 of phosphorylase, in peptide substrates of phosphorylase kinase. 
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as a positive substrate specificity determinant. The second paper is a study 
of the specificity determinants of PhK13, a peptide inhibitor, that are 
important for the inhibition of phosphorylase kinase. The third paper is a 
study of the expression, purification, and initial characterization of PhK86. 
the C-terminal autoinhibitory domain of the catalytic subunit of 
phosphorylase kinase. The fourth paper siunmarizes work with mutants of 
phosphorylase a utilized to analyze the substrate specificity of protein 
phosphatase—1. The general conclusion follows the fourth paper. References 
cited in the general introduction and general conclusion follow the general 
conclusion. 
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ARGININE TO CITRULLINE REPLACEMENT IN 
SUBSTRATES OF PHOSPHORYLASE KINASE 
A paper to be submitted to Biochemical Biophysical Research 
Communications 
Cheryl Bartleson, Siquan Luo, Donald J. Graves, and Bruce L. Martin 
Abstract 
Synthetic peptides based on residues 9 to 18 of glycogen phosphorylase 
were prepared containing citruUine at position 16, or at both positions 10 and 
16. The peptides were compared as substrates for a recombinant, truncated 
form of the catalytic subunit of phosphorylase kinase (residues 1-300). Both 
the mono-citruUine and the di-citruUine peptides were phosphorylated less 
effectively than the parent peptide; kcat/Km values were approximately 20% 
the value with the parent peptide. Incorporation of the second citrtdline had 
Little change in the effectiveness of the peptide as a substrate although the 
kinetic parameters with the citruUine peptides did show differences. The 
change in phosphorylation did not seem to result from a change in peptide 
structure. Two dimensional NMR studies of di-citruUine peptide are reported 
and show no change in the solution structure of the peptide compared to 
parent peptide. Thus, the change in kinetic parameters with the modified 
peptides seemed an effect of arginine replacement and was likely a 
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consequence of the loss of charge inasmuch as the size of arginine and 
citrulline are similar. The results also suggest that arginine-16 was more 
important for phosphorylase kinase recognition than arginine-10. This result 
was consistent with earlier studies using alanine to replace arginine in 
sjmthetic peptides as substrates for the holoenzyme form of phosphorylase 
kinase. 
Introduction 
The modification of proteins via phosphorylation and 
dephosphorylation reactions is an ubiquitous mechanism for the regulation of 
subsequent activity. The enzymes catalyzing these reactions, the protein 
kinases and phosphatases, are broadly classified by target specificity into 
serine and threonine specific, and tjnrosine specific enzymes. Protein kinases 
can readily be characterized based on primary sequence determinants as 
judged by the systematic use of synthetic peptides (1). In other studies, we 
have examined the specificity of phosphorylase kinase. Using synthetic 
peptides based on the phosphorylation site of glycogen phosphorylase, the role 
of residues surrounding the target site (serine-14 of the phosphorylase 
sequence) has been investigated (summarized in reference 2). Basic residues 
on both the amino terminal and carboxyl terminal sides of the target serine 
were foxmd to be important in recognition by phosphorylase kinase. This is 
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distinctive from most other serine protein kinases, which seem to require 
basic residues only on the amino terminal side of the target residue. These 
studies used synthetic peptides in which basic residues, lysine or arginine, 
were often replaced by alanine residues for reactions catalyzed by the 
holoenzyme form of phosphorylase kinase. Alanine differs not only in charge, 
but also in size and the effects of this replacement may have other imderlying 
causes. 
Peptidylarginine deiminase was previously used as a tool to study the 
role of arginine residues in glycogen phosphorylase function (3). Arginines 
were converted to citrxiUine by a hydrolysis reaction res\ilting in the loss of the 
positive charge with little change in the size of the side chain. The 
replacement of arginine by citruUine did have effects on the properties of 
phosphorylase with the arginine target having the greatest effect traced to 
position-16 of phosphorylase. Not surprisingly, the ability of phosphorylase 
kinase to phosphorylate the protein was affected as well. Synthetic peptides 
containing citnilline were enzymatically generated using peptidylarginine 
deiminase, from a parent peptide of residues 9 to 18 (peptide P9-18) of the 
target sequence from phosphorylase: LysArgLysGlnlleSerValArgGlyLeu. 
Both mono-citrulline and di-citruUine peptides were enzjnnatically produced. 
Difficulties analyzing citrulline content provided imcertainty about the 
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composition of the mono-modified peptide, particularly whether modification 
was position-10 or position-16 of the peptide or a mixture of both. The di-
citruUine peptide showed no arginine after amino acid analysis providing 
confidence in the composition of this variant. Phosphorylation of these 
peptides by phosphorylase kinase did show differences although a full kinetic 
analysis was not done (3). In this work, citruUine-containing peptides have 
been chemically prepared so the composition and sequence are definitively 
known. The peptides were compared as substrates for the recombinant, 
tr\mcated form of the catalytic subunit of phosphorylase kinase. Kinetic data 
were collected and can be compared to peptides containing alanine residues to 
provide information about the reqxiired properties of residues located near the 
target serine. Use of an isolated catalytic moiety of phosphorylase kinase 
removes any concern about the non-specific effects caused by the presence of 
the other subimits of the kinase. 
Experimental procedures 
Materials- Peptides used in these experiments were synthesized and 
purified to 95% purity by the Protein Facility at Iowa State University or 
QCB, Inc. (Framingham, MA). [y-32p]ATP was the product of ICN Biomedicals 
(Costa Mesa, CA). Other chemicals were from Aldrich Chemical (Milwakee, 
WI) or Fisher Scientific (Pittsburgh, PA). 
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Proteins-The recombinant, tnmcated y subunit of phosphorylase 
kinase was expressed, renatiired, and purified as described previously (4). 
Protein concentrations were determined by the method of Bradford (5). 
Peptide Phosphorylation- Kinase activity was measured as described 
(4) in 60 mM Pipes, 60 mM Tris, pH 8.2; 10 mM MgCla, 5 mM DTT; and 1 
mM [y-32p]-ATP at SCC. Reactions were initiated by the addition of enzyme 
and incubated at 30°C. After 3 minutes, 15 |il were spotted on 
phosphocellulose paper (P-81) and washed with 0.5% phosphoric acid. After 3 
washes, the filter papers were washed with 95% ethanol, dried, placed in 
scintillation fluid, and radioactivity remaining on the papers counted. Initial 
velocities were with 0.33, 0.50, 0.66, 1.0 and 2.0 mM each peptide. Each 
substrate-velocity pair was determined at least in triplicate (n=3 for P9-18, 
and n=4 for P9-18-Cit and P9-18-Cit2). Rates were converted to units of nmol 
phosphate incorporated per minute per nmol enzyme. 
Peptide Samples for NMR Spectroscopy- The di-citrulline peptide, P9-
18Cit2, was enzymatically synthesized as described (3) and purified by 
reverse phase high performance hquid chromatography. The chromatography 
was accompHshed on a Beckman 332 chromatography system on a 10 x 250 
mm Vydac Cl8 column (Hesperia, CA). Elution was performed employing a 
gradient of acetonitrile in 0.1% trifluoroacetic acid over 25 minutes. Detection 
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was done at 230 nm with a Hitachi 100-40 UV-Vis variable wavelength 
detector. Purity was confirmed by thin-layer chromatography, high-
performance hquid chromatography, and amino acid analysis on an Applied 
Biosystems Model 420A amino acid analyzer and concentration estimated by 
amino acid analysis. 
Two Dimensional NMR Spectroscopy- Two dimensional ^H-nuclear 
magnetic resonance spectra were collected on a Varian Unity-50 
spectrometer. D2O (20%) was included for field frequency lock. Both NOESY 
and TOCSY two dimensional pulse sequences were used (6-8). For the 
NOESY spectra, a mixing time of 300 milliseconds was used. For the TOCSY 
spectra, the mixing time was 30 milliseconds. Each spectrum was comprised 
of 32 or 64 FIDs of 4K data points. The sample concentration was 3.7 mM 
peptide and the pH was 5.7. The spectra were collected at 6°C. A spectral 
width of 5000 Hz was utilized with a pvilse width of 15.5 ms. 
Results and discussion 
Synthetic peptides were prepared with sequences and designations 
shown in Figure 1. Citnilline was used to replace arginine in position 16 in 
the mono-citrtdline peptide, P9-18Cit, and in both positions 10 and 16 in the 
di-citruUine peptide, P9-18Cit2. Enzymatically prepared versions of these 
modified peptides were previously reported to be substrates for 
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phosphorylase kinase (3), but no kinetic analyses were performed because of 
low availability, and uncertain composition and sequence of the modified 
peptides. Chemical synthesis abrogated these concerns. 
There were differences between the citrulline containing peptides and 
the parent peptide. Both modified peptides were phosphorylated, but more 
slowly as shown in Figure 2. The replacement of arginine-16 with citrulline 
caused a significant decrease in peptide phosphorylation and the decreased 
phosphorylation was greater in the di-citrulline peptide. Kinetic 
characterization was done and the parameters are collected in Table I. The 
parameters showed that citrulline replacement primarily caused an effect on 
the Km parameter of the peptides with a modest variation in the effect of 
citrulline replacement on the kcat parameter. Each citrulline replacement 
caused an increase in Km. Citrulline at position 16 only (peptide P9-18Cit) 
caused a 3-fold increase in Km- Change of arginine at position 10 also had an 
efiect on the Km parameter, but the effect was less than 2-fold compared to 
P9-18Cit. In previous studies (2) replacement of arginine-10 alone with 
alanine had virtually no effect on the kinetic parameters. Replacement of 
arginine with lysine did cause changes in the kcat parameter with little 
difference in Km; the kcat term was reduced 100-fold. Replacement of arginine-
16 with alanine or glycine did affect both kinetic parameters detrimentally. 
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although the greatest effect was on kcat- No di-alanine containing peptide was 
tested. Comparing these data, it seems that it was the loss of charge that 
most influenced the Km for peptides with phosphorylase kinase. Only with the 
loss of size as in the alanine peptides did the kcat values get drastically 
influenced. CitruUine replacement did not cause similar declines in kcat. It 
seems that charge is the critical requirement at position 16. 
These data suggest that arginine replacement by citruUine had 
consequences on peptide phosphorylation. A possible basis for charge 
recognition is a change in the overall structiire of the citridline peptides in 
solution. Two dimensional NMR was used to compare the solution structures 
of peptides P9-18 and P9-18Cit2. Previously, we reported that NMR studies 
of peptide 9-18 showed little secondary structure for this peptide at pH 5.7 
(9). The same NMR studies were done on the di-citrulline peptide and only 
this peptide was characterized as it was expected to show the most 
significant differences in structure. Peptide P9-18Cit2 showed little 
secondary structure. There were few cross peaks evident in the spectrum 
suggesting Uttle interaction between residues. The complete assignment of 
resonance for the di-citrulline peptide was done and resonances are shown in 
Table II with assignments for the parent peptide included for comparison. 
There were little differences between assignments consistent with similar 
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structures of the peptides. The notable difference was the e-nitrogen 
hydrogens for the arginine or citruUine residues. In both P9-18 and P9-
18Cit2, the residues showed no difference between positions 10 and 16. 
Collectively, these data support the conclusion that arginine-16 in 
glycogen phosphorylase is involved in the recognition and effective 
phosphorylation of phosphorylase by phosphorylase kinase. The positive 
charge is not an absolute requirement consistent with earlier suggestions 
(2,3), but phosphorylase kinase did prefer positive charge on the carboxyl side 
of the target serine for most effective phosphorylation of substrate. Based on 
comparisons to the cAMP dependent protein kinase, residues of the y-subunit 
predicted to interact with the P+2 position are present in sub-domains II and 
in (nomenclature of Hanks, et al., 10). There is an unique insert containing 
three glutamic acid residues, E61-E62-V63-Q64-E65, in this part of the 
protein. Recently, a role for positive charge in this position was further 
supported by the characterization of the crystal structure of a similar form of 
the catalytic subunit (residues 1-298) complexed with a heptapeptide (see 
Figure 1) containing an arginine in the P+2 position as the penidtimate 
residue (11). The sequence of this heptapeptide is similar to preferred 
sequences identified by screening a synthetic peptide Library (12) yielding 
peptides with Phe, Arg, or Lys in the P+2 position. The resolved crystal 
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structure suggested that the arginine in the P+2 position was oriented toward 
a glutamic acid residue, Glu-182, of phosphorylase kinase. Clearly, charge 
interactions between the P+2 arginine and Glu-182, or another glutamate 
residue, wotdd facilitate more effective interaction of the substrate with the 
enzyme. Conversion to citridline in position 16 may weaken this interaction 
resulting in poorer substrate turnover. 
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P9-18 Lys Arg Lys Gin He Ser Val Arg Gly Leu 
P9-18Cit Lys Arg Lys Gin lie Ser Val Cit Gly Leu 
P9-18Cit2 Lys Cit Lys Gin He Ser Val Cit Gly Leu 
MC peptide Arg Gin Met Ser Phe Arg Leu 
Figure 1. Sequences of the substrate peptides. The sequences of the 
different peptides are shown illustrating the position of 
citrulline incorporation. The heptapeptide variant used in 
crystallographic studies is also shown. 
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Figure 2. Phosphorylation of P9-18 peptides. Substrate peptides were 
phosphorylated as described in the text. The concentration of 
each peptide was 1.0 mM. 
Table I Kinetics of Peptide Phosphorylation 
Substrate Peptide kcat (min ') Km (mM) 
Recombinant Catalytic Subunit-Truncated Fragment of Residues 1-300 
P9-18 3410+ 119 0.26 + 0.03 
P9-18Cit 2396 + 277 0.81 + 0.20 
P9-18Cit2 3293 + 157 1.44 + 0.12 
Holoenzyme Studies (Calculated from Reference 2) 
P9-18 3771 + 351 0.9 + 0.2 
P9-18 10-Ala 3511 + 247 0.9 + 0.3 
P9-18 16-Ala 234 + 4 2.3 + 0.04 
P9-18 16-Gly 156 + 2 1.0 + 0.12 
kcnt/Kni 
13170 (1.00) 
2951 (0.22) 
2284 (0.17) 
4190 (1.00) 
3901 (0.93) 
102 (0.02) 
156 (0.04) 
Table II Resonance Assignments for Di-Citrulline and Parent Peptides 
P9-18Cit2 
Residue g-NH g-CH &-CH X-CH 
Lys-9 3.89 1.82 1.42 
Cit-10 8.42 4.25 1.79 
1.70 
1.51 
Lys-11 8.60 4.21 1.74 1.41 
Gin-12 8.55 4.34 1.95 
2.03 
2.32 
110-13 8.44 4.16 1.84 1.17 
Ser-14 8.51 4.51 3.82 
Val-15 8.38 4.13 2.09 0.91 
Cit-16 8.42 4.29 1.79 
1.70 
1.51 
Gly-17 8.44 3.90 
Leu-18 7.80 4.19 1.56 1.56 
8-CH £-NH Other 
2.97 
3.08 6.39 
2.97 
0.84 0.88 1.45 
(P-CHa) (Y-CHa) 
3.08 6.39 
P9-18 
Residue a-NH a-CH 
Lys-O 
Arg-10 8.43 4.31 
Lys-ll 8.66 4.23 
Gln-12 8.60 4.34 
Ile-13 8.43 4.18 
Ser-14 8.53 4.52 
Val-15 8.39 4.13 
Arg-16 8.48 4.29 
Gly-17 8.45 3.91 
Leu-18 7.86 4.19 
Table II (continued) 
fi-CH x-CH 8-CH £-NH Other 
1.79 1.63 3.19 7.22 
1.75 
1.96 
2.03 
2.33 
1.84 
3.83 
2.08 
1.85 
1.75 
1.17 
1.63 
0.90 
3.16 7.22 
0.84 1.45 
(P-CHs) (y-CHs) 
1.57 1.57 0.89 
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SPECIFICITY DETERMINANTS OF PHK13 IMPORTANT 
FOR THE INHIBITION OF PHOSPHORYLASE KINASE 
A paper to be submitted to the Journal of Biological Chemistry 
Cheryl Bartleson and Donald J. Graves 
Abstract 
The C-terminus of the catalytic y subunit of phosphorylase kinase 
contains two autoinhibitory calmodidin binding domains, designated PhK13 
and PhK5. Peptides of these sequences inhibit trxmcated 7(1-300). Previous 
data show that the peptide PhKl3, residues 302-326, is a competitive 
inhibitor with respect to phosphorylase b, with a Ki of 1.8 ^ iM (1). This result 
suggests that PhK13 could bind to the active site of trxmcated 7(1-300). 
Variants of PhK13 were prepared to localize the determinants for interaction 
with the catalytic fragment 7(1-300). A dodecapeptide, PhKl3-l, containing 
residues 302-312, was foimd to be a competitive inhibitor with respect to 
phosphorylase b, with a Ki of 6.0 nM. PhKl3 has been proposed to function as 
a pseudosubstrate inhibitor, with C308 occupying the site that normally 
accomodates the phosphorylatable serine in phosphorylase b. To test this 
pseudosubstrate h5T)othesis, a PhK13-l variant changing C308 to serine was 
synthesized. Kinetic characterization of this peptide reveals it does not serve 
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as a substrate, but is a competitive inhibitor. Thus, additional PhK13-l 
variants were designed based on previous knowledge of phosphorylase kinase 
substrate determinants. Each variant was analyzed both for its ability to 
serve as a substrate, and as an inhibitor for trtmcated 7(1-300). 
The inabihty to convert PhKl3-l into an efficient substrate resulted in 
questioning whether PhKl3-l could bind to the active site. Competitive 
inhibition is consistent with active site binding but does not prove active site 
binding. Additional analysis of the ATPase activity of trimcated 7(1-300) in 
the presence and absence of PhK13-l resulted in inhibition of the ATPase 
activity by PhKl3-l, 
PhK13-l is a potent competitive inhibitor of phosphorylase kinase, 
with respect to phosphorylase b phosphorylation and ATPase activity. 
Although PhKl3-l does not appear to function as a pseudosubstrate 
inhibitor, several specificity determinants employed in the recognition of 
phosphorylase b as substrate seem to be employed in the recognition of 
PhK13-l as an inhibitor. 
Introduction 
The catalytic activity of many protein kinases appears to be 
regulated by an autoinhibitory mechanism, also known as intrasteric 
regulation (2,3). Many autoinhibitory domains were discovered by the 
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observation that numerous proteolyzed or truncated forms of these 
protein kinases resulted in activation. The autoinhibitory domain often, 
but not always, resembles the consensus sequence of an enzyme's 
substrate. Protein kinase A was the first described case of intrasteric 
regxilation by a pseudosubstrate domain located on the regulatory 
subunit (4-6). Substantial evidence exists impHcating this mechanism 
in protein kinase G, protein kinase C, myosin hght chain kinase, 
twitchin, calmodulin-dependent protein kinase I and phosphorylase 
kinase (2,3,7,8)-
Phosphorylase kinase is a member of the Ca^^ /calmodulin-
dependent protein kinase family. Members of the Ca^-^ /calmodulin-
dependent protein kinase family, myosin hght chain kinase, calmodulin-
dependent protein kinases I, II, IV, and phosphorylase kinase contain an 
autoinhibitory domain, which overlaps the calmodvdin binding regions 
(2,3). A possible mechanism for this intrasteric regulation is that the 
autoinhibitory domain occupies the enzyme's active site and binding of 
calmodvdin in the presence of calcixmi induces a conformational change 
releasing the autoinhibitory domain firom the active site, thus activating 
the enzyme. Alternatively, the autoinhibitory domain could bind outside 
of the active site and influence the active site indirectly. Binding of 
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calmodulin in the presence of calciimi to the autoinhibitory domain 
would result in a conformational change that is transmitted to the active 
site and results in activation of the enzjone. 
Phosphorylase kinase catalyzes the conversion of phosphorylase b, 
inactive, to phosphorylase a, active, by phosphorylating serine residue 
14. This reaction is highly specific. Phosphorylase kinase is the only 
protein kinase known to catalyze this reaction in vivo. Holoenzyme 
phosphorylase kinase has a molecular mass of 1300 kDa. It is comprised 
of a hexadecamer, containing four of each of the four subunits, (aPY5)4. 
The a and P subvmits are regulatory. The 5 subimit is equivalent to 
bovine brain calmodulin and confers calcium sensitivity to the enzyme. 
The Y subunit is the catalytic subimit. 
The N-terminal 300 amino acids of y encompass the catalytic 
domain of phosphorylase kinase. The C-terminal 86 amino acids contain 
two non-contiguous high affinity calmodvdin binding segments, PhK13, 
residues 302-326, and PhK5, residues 342-366 (9) (Figure 1). The catalytic 
Y subxinit is unique in that the 5 subunit remains tightly bound in the 
absence of calciimi and the autoinhibitory C-terminal domain is comprised 
of two calmodulin binding domains. Dasgupta et al. determined the Ki 
values for PhK13 and PhK5 utilizing holoenzyme phosphorylase kinase to 
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be 300 nM and 20 fiM, respectively (10). These values fall into the range of 
Ki values obtained with other protein kinase autoinhibitory domains (2,3). 
The peptides PhK13 and PhK5 differentisdly inhibit truncated y (1-300). 
Previous data show that PhKlB is a competitive inhibitor with respect to 
phosphorylase b, with a Ki of 1.8 |iM (1), suggesting that PhK13 may act as 
a pseudosubstrate with cysteine 308 occupying the site corresponding to the 
serine of the phosphorylatable substrate. Figure 2 illustrates the 
ahgnment of PhKl3 with 9-18, the peptide substrate derived from the 
phosphorylatable sequence of phosphorylase b. 
Kinetic studies utilizing two truncated 7(1-300) mutants, EllOK 
and E153R, with charge reversals of 9-18 peptide, demonstrated that 
these mutants recognize the P"^ Gysine) and P-2 (glutamine) 
positions/residues of substrate, respectively (1). The crystallization of 
triincated 7(1-300) with a peptide substrate confirms this assignment 
(11). PhK13 contains a lysine at P-3 and a valine at P-2. Analysis of PhK13 
binding to the truncated 7(1-300) mutants EllOK and E153R resulted in 
increasing Ki's for PhKl3, compared to wild-type truncated 7(1-300). The 
K, increased 14-fold with EllOK and 8-fold with E153R (1). These resialts 
are consistent with PhK13 binding to the active site of truncated 7(1-300). 
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The aim of this work was to test the hypothesis that PhK13 
functions as a pseudosubstrate inhibitor. Conversion of PhK13 from an 
inhibitor to a substrate would be indicative of active site binding. In lieu 
of structural information, this would support the model, in which the C-
terminus of phosphorylase kinase interacts directly with the active site, as 
is observed with twitchin kinase. In addition the specificity determinants 
of PhK13 important for the inhibition of phosphorylase kinase were 
examined in an effort to further our understanding of this molecular 
interaction. 
Experimental procedures 
Materials- [y-^^PJ-ATP was purchased from ICN Biomedicals (Costa 
Mesa, CA). All other reagents were commercially available from Fisher 
(Pittsburgh, PA), Sigma (St. Louis, MO) or Boehringer Mannheim 
(IndianapoHs, IN). Phosphorylase b was ptirified as described (12). 
PhKlS, "/residues 302-326, PhKl3 analogs, residues 302-314, 9-18 
peptide, residues corresponding to the phosphorylatable region of 
phosphorylase b, were synthesized at the Iowa State University Protein 
Facility. All peptides were purified by reverse-phase HPLC utihzing a 
C18 column. 
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Peptide Concentration Z)eiermimziions-Peptide concentrations were 
determined by amino acid analysis at the Iowa State University Protein 
Facility and by DTNB titration for the cysteine containing peptides (13). 
Expression, Purification, and Renaturation of Truncated ySubunit-
Tramcated Y(1-300) was expressed, ptirified, and renatured as previously 
described (14). Recombinant tnmcated Y(1-300) was purified to homogeneity 
as judged by SDS-PAGE (data not shown). Protein concentrations were 
determined by Bradford assay with commercially prepared reagents from 
BioRad (Hercules, CA) (15). 
Activity Assay-The protein kinase activity of tnmcated Y(1-300) was 
determined by incorporation into phosphorylase b as previously described 
with minor modification (16,17). The standard activity assay contained 50 
mM PIPES, 50 mM Tris, pH 8.2, 10 mM MgCh, 10 mg/ml phosphorylase b, 5 
mM DTT, ImM [Y-32P]-ATP, and 0.5 |ig/ml tnmcated Y(1-300). The reaction 
is performed at 30°C and initiated by the addition of enzyme. After 
incubation 15 |j1 of reaction mixture was spotted on ET-31 Whatman filter 
paper, and washed with trichloroacetic acid (18). The radioactivity 
incorporated was determined by liquid scintillation counting. 
Substrate Analyses-AIL peptides were first evaluated as substrates for 
tnmcated 7(1-300) using the standard activity assay, but with non-
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radioactive ATP, and peptide concentrations of 1-2 mM. These samples were 
analyzed by MALDI-TOF-MS using a Finnigan Lasermat 2000, with equal 
molar ratios of ACH matrix to peptide, in the Iowa State University Protein 
Facility. The second evaluation of peptides as substrates for truncated y(l-
300) utilized the standard activity assay with [y-^zpj-ATP. 
Inhibition Studies-ln the inhibition assay (Figure 3), the standard 
activity assay was used except, for the addition of PhK13-l and the final 
concentration of phosphorylase b was 4 (iM. In the kinetic analyses (Table II), 
the concentration ranges of phosphorylase b varied from 4 |iM-90 
inhibitor peptide concentrations varied from IjiM-lmM and the concentration 
of ATP was fixed at ImM. 
Kinetic data were analyzed with either Enzfitter (Elsevier Science 
Publishers) or Enzyme Kinetics (Trinity Software). The inhibition data were 
fitted to equations for competitive or non-competitive inhibition. The 
inhibition constants were determined from the linear secondary plots (data 
not shown). All analyses were repeated a minimum of three times in 
triplicate. 
ATPase Assa^'s-ATPase assays were performed at 30°C as described 
(19). Final concentrations of reagents in the assay were as follows; 50 mM 
Hepes, pH 8.2, 0.1 mM DTT, 20 mM MgCla, 1 mM ATP. Reactions were 
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initiated by the addition of truncated 7(1-300) to a final concentration of 10 
M-g/ml. PhKl3-l concentrations varied from 0.1 nM —500 jiM. At the 
specified time 20 ^il aliquots were removed from the assay mixture and 
pipetted into vials containing 20 (il of a mixtiure of 2.8 N sulfuric acid, 4.3% 
silicotxmgstic acid, plus 100 ^il of an organic mixture containing benzene and 
isobutanol, 1:1. After mixing the solution, 20 (J1 of 10% ammonium 
molybdate was added and the sample vortexed for 10s. An aliquot of 20 
was removed from the upper organic phase and spotted on ET31 Whatman 
filter paper. Liquid scintillation counting was used to determine the amount 
of [32p].p| released. 
Results 
IdentificatioTL of Inhibitory Section of PhKl3- A variant of PhKl3 was 
prepared to localize the determinants for interaction with trimcated Y(1-
300). A dodecamer of the N-terminus of PhKl3, PhKl3-l, 
GiCFKVICLTVXA, containing cysteine 308 inhibits tnmcated Y(1-300) 
(Figure 3). A peptide of the C-terminus of PhK13, LASVRIYYQYRRVKP, 
does not inhibit (10), suggesting that the major interaction in the active 
site occurs through the segment containing cysteine. PhK13-l was a 
competitive inhibitor of truncated 7(1-300), with respect to phosphorylase 
b, and has a Ki of 6 jiM (Table II). 
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Pseudosubstrate Analysis of PhKlS-Maxime is the most common amino 
acid occupjdng the phosphate acceptor site in autoinhibitory and/or 
pseudosubstrate domains (3). In many autoinhibitory protein kinases, 
substitution of this alanine residue to serine resulted in conversion of the 
inhibitor to a substrate. If cysteine 308 occupies the phosphate acceptor site, 
does the equivalent serine substituted peptide then serve as a substrate? 
We made the PhK13-l variant, PhK13-l(C308S), changing C308 to serine. 
Based on our knowledge of phosphorylase kinase substrate specificity, this 
PhK13-l(C308S) peptide was expected to function as a substrate. This 
vEiriant was analyzed as a substrate using 9-18 peptide as a comparison, but 
we were unable to detect any phosphorylation in this peptide using MALDI-
TOF MS (Figure 4). Analysis of PhK13-l(C308S) as an inhibitor 
demonstrated that this variant is a competitive inhibitor of truncated 7(1-
300) with respect to phosphorylase b. The change of C308S resulted in the K, 
increasing 30-fold, from 6 pM to 175 |iM (Table II). 
Inhibitor Specificity Determinants-To leam more about the contribution 
of other residues in the sequence of PhK13-l, additional PhKl3-l variants 
were designed based on prior knowledge of phosphorylase kinase substrate 
determinants. Residues previously shown to affect specificity of 
phosphorylase kinase for phosphorylase were systematically substituted 
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(20). Table I lists the PhK13-l variants designed. PhK13-l(F304E/C308S) 
adds a basic residue in the P-* position, since phosphorylase b contains an 
arginine at P"*. The optimal sequence derived from peptide library work 
places a phenylalanine at P '*, implying that phenylalanine can be 
accommodated in this position (21). PhKl3-l(V306Q/C308S) replaces 
valine with glutanune at P-2. The recent crystal structure of truncated y(1-
298) complexed with a modified version of the optimal library sequence 
indicates that valine should fit in place of glutamine (11). In the library 
sequence, a methionine residue was selected in this position (21). Arginine 
in the P^^ position has been shown to be a positive determinant for 
phosphorylase kinase recognition and this substitution resulted in peptide 
PhK13-l(C308S/T310R). Each of these peptides was analyzed for its ability 
to serve as a substrate of truncated 7(1-300). As evident from the apparent 
lack of detectable phosphorylation by MA LP I analysis or 32-P incorporation, 
none of the PhK13-l variants listed in Table I were able to function as 
substrates for trxmcated Y(1-300) (data not shown). Every PhKl3-l variant 
was a competitive inhibitor of trimcated 7(1-300) with respect to 
phosphorylase b as substrate. The resulting changes in inhibition constants 
varied widely, depending on the substituted amino acid residue. Table II 
summarizes these results. 
48 
Inhibition Analysis of PhKl3-l/RG Variants-T^o additional PhKl3-l 
variants were designed (Table HI). The glycine residue at found in 
phosphorylase b, neurogranin, and neuromodulin was incorporated into 
PhK13-l (22). The first glycine variant PhK13-l(C308S/T310RAr311G) 
tested up to ImM, no longer inhibited truncated 7(1-300) (data not shown). 
This peptide variant was phosphorylated as analyzed by MALDI-TOF MS, 
using 9-18 peptide as a positive control (Figure 5). Phosphorylation of this 
peptide proceeded at a much reduced rate, approximately 100 fold less, when 
compared to 9-18 peptide (Figure 6). Additional kinetic analysis was not 
performed. The resulting conversion of this peptide fi:om inhibitor to 
substrate by the incorporation of glycine could change the orientation of the 
serine. If incorporation of glycine does change the orientation of serine, then 
the corresponding peptide with cysteine would also change in orientation. This 
potential change in orientation could weaken the interaction with truncated 
7(1-300) and we may no longer observe inhibition with the peptide PhKl3-l 
(TSIORA'^SIIG). Initial results with peptide PhKl3-l (T310IW311G) show 
no inhibition of truncated 7(1-300) with peptide concentrations up to 400 
(Figure 7). 
ATPase Aciiuify-Substitution of serine for cysteine resulted in much 
poorer inhibitor. The distance between the 7 phosphate of ATP and the 
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acceptor residue might be changed in the presence of the larger cysteine 
residue. Although there is no evidence for cysteine phosphorylation by a 
protein kinase catalyzed reaction, if the cysteine residue in PhK13-l is in 
closer proximity to the y phosphoryl group of ATP, it may affect the ATPase 
activity of trxmcated y(1-300). Phosphorylation could occur, but because a 
cysteine phosphate would be very labile, it could break down and re-form, 
making the product extremely difficult to detect. One way to test this 
h3T>othesis is to examine the ATPase activity of truncated 7(1-300) in the 
presence and absence of PhK13-l. Protein kinases have a small intrinsic 
hydrolytic activity towards ATP. They are able to utilize the hydroxyl group 
of water as a phosphate acceptor at a very slow rate. ATPase activity is 
monitored by detecting the release of Pi. Thus, if truncated y(1-300) was 
attempting to utilize the cysteine as a phosphate acceptor, we should detect 
an increase in the amounts of Pi released in the presence of PhK13-l when 
compared to the ATPase activity of trxincated y(1-300) alone. Alternatively, 
the peptide PhKl3-l could block access of water into the active site, thus 
preventing ATPase activity. Initial results on the analysis of the ATPase 
activity reveal that PhK13-l inhibits the ATPase activity of truncated 7(1-
300) (Figure 8). This result indicates that PhK13-l may bind tightly, filling 
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the active site, and either exclude water from entering or disrupt the y 
phosphate orientation so that ATPase activity is diminished. 
Discussion 
A dodecamer of the N-terminus of PhK13, PhK13-l, 
GKFKVICLTVLA, containing cysteine 308, was a competitive inhibitor 
with a Ki of 6 |iM. The low Ki of PhK13-l, compared to the Ki of 1.8 jiM for 
PhK13, indicates that most the residues important for the inhibition of 
truncated 7(1-300) are located in the N-terminal half of PhK13. 
Conversion of PhKl3-l to a potential substrate for truncated 7(1-300) 
by changing C308 to serine was unsuccessful. If upon PhK13-l(C308S) 
binding, the seryl group could not reach the terminal 7 phosphoryl group of 
ATP, this peptide would not serve as a substrate, but it could act as a 
competitive inhibitor. Indeed, PhK13-l(C308S) competitively inhibits 
truncated 7(1-300). The Kiof PhK13-l(C308S) increases 30 fold over the Ki of 
the parent peptide, PhK13-l, from 6 [iM to 175 ^iM. 
Further analysis of the specificity determinants in PhK13-l identified 
other potentially important residues, in addition to cysteine 308, that are 
involved in the inhibition of trtincated 7(1-300) by PhK13-l. The increase in 
K. from 175 [iM in PhK13-l(C308S) to 802 ^lM in PhK13-l(F304R/C308S) 
indicates that phenylalanine in the P-4 position is an important specificity 
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determinant for inhibition. This phenylalanine is eqmvalent to the 
conserved hydrophobic anchoring residue found in many calcium, calmodulin-
dependent protein kinases. This hydrophobic anchoring residue is important 
for calmodulin binding as well as inhibition. The Km for 9-18 peptide, 
containing arginine in the equivalent position, is ImM. Substitution of 
arginine for phenylalanine raised the Ki close to the mM range. Inclusion of 
the arginine at P+2 decreased the Ki down to an 8-fold difference, when 
compared to PhK13-l, emphasizing the preference phosphorylase kinase has 
for arginine at 
The inability of the glycine variant, PhK13-l(C308S/RG), to inhibit 
truncated Y(1-300) is consistent with previous results utilizing a cysteine 
substituted 9-18 peptide substrate, KRKQICVRGL, which does not inhibit 
truncated 7(1-300), and does not serve as a substrate (23). Previous work 
utilizing a cysteine substituted Kemptide, LRRACLG, showed that this 
peptide was unable to function as a substrate for protein kinase A (24). 
Although this peptide could serve as an inhibitor of protein kinase A with 
respect to Kemptide, the Ki of 1.9 mM is very high compared to the 
micromolar Km of Kemptide (24). This suggests that the valine-leucine pair 
found in PhKl3-l, and several of the variants, is causing steric interference 
and changes the position of the substituted serine residue. The substitution 
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of glycine for valine could relieve this interference, enabling phosphorylation of 
the peptide substrate. 
PhK13-l is a much better inhibitor than PhK13-l(C308S). What 
characteristics of cysteine make it a better inhibitor than serine? Many 
protein kinase pseudosubstrates contain alanine in the phosphoacceptor 
position. Alanine has a smaller hydrophobic side chain than cysteine, 
although the size of an alanine chain side would be closer to that of serine. 
The larger cysteine may change the distance between the y phosphate of 
ATP with respect to the acceptor residue. This could result in the SH- of 
cysteine causing steric interference with the ypliosphate of ATP. 
Alternatively, PhK13-l binding to truncated 7(1-300) could fill the active 
site, excluding water. Elimination of water in the active site would prevent 
ATPase activity. The inhibition of ATPase activity in the presence of 
PhKl3-l supports PhKl3-l binding to the active site of trtmcated y(1-300). 
Competitive kinetics obtained for the PhKl3-l variants is consistent 
with these peptides binding at the active site. Previous data firom this lab 
utilizing charge reversal mutants of truncated y(1-300) with PhK13 
supports PhK13 binding at the active site. The mutants EllOK and E153R 
exhibited higher Ki values with PhK13 than trxmcated 7(1-300), and PhK13 
remained a competitive inhibitor. However, the lack of phosphorylation 
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observed for the majority of PhK13-l variants is troublesome. An 
alternative possibility is the binding of PhK13-l at another site on 
trimcated 7(1-300), that is distinct from the active site. Binding of PhK13-
1 at this site coxild alter the conformation or orientation of the N- and C-
terminal lobes of the catalytic kinase core, thus altering the active site. A 
change in conformation around the active site could result in altering metal 
ion binding, ATP binding, the orientation of the catalytic base, and/or the 
binding of substrate. Structural evidence exists that illustrates each 
possibility. The crystal structvire of twitchin kinase reveals the C-terminal 
autoinhibitory domain extends through the active site, making extensive 
contacts with the active site, and passes over the activation loop (25). The 
more recent crystal structiure of /calmodulin-dependent protein kinase 
I shows the C-terminal autoinhibitory domain making multiple contacts 
with the surface of the large lobe of the catalytic core, but then txims away 
from the activation loop and travels along the small lobe (26). Recent work 
from small x-ray and neutron scattering resulted in a structiire for myosin 
light chain kinase complexed with calmodulin. Calmodulin was near the 
catalytic core, but away from the active site, suggesting displacement of the 
automhibitory domain. The additional structxire has been expanded to 
include the substrates AMP-PNP and a peptide substrate derived from the 
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regulatory light chain (27). Here the overall complex becomes more 
compact, i.e. "closed", jdelding the active conformation of a protein kinase. 
It is not currently possible to definitely distinguish which of these modes of 
binding will ultimately be utilized by the autoinhibitory C-terminus of 
phosphorylase kinase. Thus, the exact binding of PhKl3-l awaits 
structural determination. 
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Figure 1. Schematic of the catalytic subunit y of phosphorylase kijiase. 
The N-terminal region of 7, residues 1-276, has homology to the catalytic domains of other 
protein kinases. The C-terminal region, residues 276-386, contains two non-contiguous high 
affinity calmodulin binding domains, PhK13, resides 302-326, and PhK5, residues 342-366. 
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Figure 2. Sequence alignment of PhK13 with the phosphorylatable 
region ofphosphorylase_b. 
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Figiire 3. Inhibition of truncated "^l-SOO) by PhKl3-l. 
% Activity of trxmcated Y(1-300) verus [PhK13-l] 
varied from 0-50 |xM. Phosphorylase was used as 
substrate. Assay described in Experimental 
procedures. 
TABLE I Sequence Comparisons of Peptide Substrates and 
Inhibitors of y (1-300) 
9-18 
PhK13-l 
PhK13-l(C308S) 
PhK13-l(F304R/C308S) 
PhK13-l(V306Q/C308S) 
PhK13-l(C308S/T310R) 
K-R-K-Q-I-S-V-R-G-L 
G-K-F-K-V-I-C-L-T-V-L-A 
G-K-F-K-V-I-S-L-T-V-L-A 
0> 
G-K-R-K-V-I-S-L-T-V-L-A 
G-K-F-K-^-I-S-L-T-V-L-A 
G-K-F-K-V-I-S-L-R-V-L-A 
Figure 4. MALDl Spectra of 9-18 compared to PhK13- IS, 
MALDI spectra of 9-18 peptide and reaction product compared with the 
PhK13-IS peptide and reaction product. Reactions conditions described 
under Experimental procedures. Panel A is the 9-18 spectra, showing the 
predicted weight of 1180, and panel B is the reaction spectra, with the 
expected product peak at 1259. Panel C is the PhK13-lS peptide spectra. 
Panel D is the PhKl3-lS reaction spectra. 
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Table II Ki values and kinetic mechanisms for the inhibition of truncated y (1-300) 
Y (1-300) form PhK 13 variant Mode of inhibition Ki (jlM) 
wild-type GKFKVICLTVLA Competitive 6+1 
wild-type GKFKVISLTVLA Competitive 175 + 3 
wild-type GKRKVISLTVLA Competitive 802+ 1,5 
wild-type GKFKVISLTVLA Competitive 80 + 5 
wild-type GKFKVISLRTVLA Competitive 44 + 4 
TABLE III Sequences of PhK13 Glycine Variants 
9-18 KRKQISVRGL 
PhKl 3-1 GKFKVICLTVLA 
a 
PhKlS-KCSOSS/TSlORWailG) GKFKVISLRGLA 
PhK13-l(T310RW31lG) GKFKVICLRGLA 
Figure 5. MALDI Spectra of PhKl3-l S/RG. 
MALDI spectra of the PhK13-l S/RG peptide and reaction product. 
Reaction conditions described under Experimental procedures. Panel A 
is the spectra of PhK13-lS/RG peptide and panel B is the spectra of the 
reaction product indicating that no phosphorylated product is observed. 
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Figure 6A. [32P] incorporation into peptide 9-18. 
Panel A is the reaction with 9-18. Assay conditions 
are described in Experimental procedures. The 
concentration of 9-18 peptide was ImM. 
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Figvire 6B. [32P] incorporation into peptide PhK13-l(S/RG). 
Panel B is the reaction with PhK13-l(S/RG). 
Assay conditions are described in Experimental 
procedures. The concentration of PhK13-l S/RG 
was 2mM. 
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Figure 7. Inhibition of truncated y(l-300) by PhKl3-l/RG. 
% Activity of trimcated 7(1-300) in the presence of 
peptide PhK13-l/RG. Assay conditions were as 
described under experimented, procedures. The 
amounts of PhK13-l/RG are as indicated. 
Figure 8. ATPase inhibition by PhK13-l. 
% ATPase activity in the presence of increasing amounts of PhK13-l. 
Assay conditions described in experimental procedures. The concentrations 
of PhK13-l utilized are as indicated. 
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EXPRESSION AND ANALYSIS OF PHK86, THE 
AUTOINHIBITORY CALMODULIN BINDING C-
TERMINUS OF THE CATALYTIC SUBUNIT OF 
PHOSPHORYLASE KINASE 
A paper to be submitted to the Joximal of Biological Chemistry 
Cheryl Bartleson and Donald J. Graves 
Abstract 
The N-terminus, residues 1-296, of the catalytic y subxmit of 
phosphorylase kinase has homology to the catalytic domains of other protein 
kinases. The C-terminus, residues 297-386, contains two non-contiguous high 
affinity, autoinhibitory calmodulin-binding regions, designated PhK13 and 
PhK5. Peptides of these sequences differentially inhibit truncated 7(1-300). 
PhK13, residues 302-326, is a competitive inhibitor and PhK5, residues 342-
366, is a non-competitive inhibitor. Although the crystal structure of the 
truncated 7(1-298) has been solved, no structural information is available on 
how the C-terminus binds to tnmcated 7(1-298). Previous attempts to purify 
full-length 7 in amounts suitable for structure/function studies have been 
imsuccessful due to proteolysis at the C-terminus. We have expressed the C-
terminus of the catalytic 7 subunit, referred to as PhK86. PhK86 
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encompasses both the PhK13 and PhK5 regions. Expression of PhK86 as a 
histidine-tagged fusion protein in E. coli resulted in formation of insoluble 
inclusion bodies. A purification and renatiu-ation protocol has been developed 
that will lead to successful production of amounts of PhK86 suitable for 
structxire/function analyses. Renatured PhK86 appears functional. PhK86 
binds calmodulin and truncated 7(1-300). Initial results with eluted PhK86 
indicate that PhK86 inhibits tnmcated 7(1-300) with respect to 
phosphorylase b. 
Introduction 
Phosphorylase kinase plays a key regulatory role in glycogen 
metabohsm by catalyzing the phosphorylation of glycogen phosphorylase 
kinase, which converts phosphorylase b, inactive, to phosphorylase a, active. 
The enzyme is a hexadecamer with a subunit composition of (a,p,7,8)4, and a 
molecular weight of 1300 kDa. The a, Mr, 138 kDa, and p, Mr 125 kDa, are 
regidatory subunits that can be phosphorylated by protein kinase A and nan 
bind exogenous calmodulin, 6'. The 7 subunit, Mr 45 kDa, is the catalj^ic 
sub unit. The 5 subunit, Mr 17 kDa, is almost identical to bovine brain 
calmodulin and confers calcium sensitivity to the enzyme. Phosphorylase 
kinase is distinct from many other calmodulin-regulated systems, in that 
tight binding of the 5 subimit occxirs in the absence of calcium (1). 
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The catalytic activity of many calcixim-ca Imodulin regulated protein 
kinases appears to be regulated by an autoinhibitory mechanism (2-4). Many 
autoinhibitory domains were discovered by the observation that proteolyzed 
or truncated forms of these protein kinases resulted in activation. The 
autoinhibitory domain is often located in the C-terminus near or overlapping 
the calmodulin binding region. The proposed mechanism for this intrasteric 
regulation is that the autoinhibitory domain occupies or blocks access to the 
enzyme's active site. The binding of calmodulin, in the presence of calcium, 
induces a conformational change that releases the autoinhibitory domain, 
activating the enzyme. 
The C-terminus, PhK86, of the cataljrtic y subimit of phosphorylase 
kinase contains two non-contiguous autoinhibitory calmodulin binding 
domains (5). Although, the crystal structure of trxmcated Y(1-298) has been 
solved, no structural information is available on how the C-terminus, PhK86, 
interacts with the catalytic core and the other subimits of phosphorylase 
kinase to regulate activity (6). 
The full-length Y subrmit (1-386) has been expressed in E. coli and 
insect cells by ovir laboratory and others (7-9). Unfortimately, due to 
proteolysis during purification, attempts to produce svifficient amoimts of full-
length Y suitable for structural studies has been vmsuccessful. As a result. 
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most work has been done utilizing a tnmcated form of y, residues 1-300, that 
can be expressed, purified, and renatxired firom inclusion bodies (7). In the 
absence of full-length y, an alternative is to express the regulatory domain, 
PhK86. PhK86 must be generated in quantities suitable for 
structiire/function studies in order to determine how it interacts with the 
kinase core of phosphorylase kinase, in addition to interactions that would be 
present with the other subunits in holoenzyme. 
Experimental procedures 
Materials-A}l chemicals were purchased firom Boehringer Mannheim 
(Indianapolis ,IN), Sigma (St. Louis, MO), or Fisher (Pittsburgh, PA). 
Restriction enyzmes and T4 DNA ligase were firom New England Biolabs 
(Beverly, MA). The pET15b plasmid and E. coli BL21(DE3) were purchased 
firom Novagen (Madison, WI). Isopropyl-P-D-thiogalactop5nranoside was 
purchased firom 5 Prime-3 Prime (Boulder, CO). The immobilized metal 
affinity chromatography, IMAC, utilized were either, the Ni2+-based His-
Resin firom Novagen (Madison, WI), or the Co^-^ based TALON resin firom 
Clontech (Palo Alto, CA). The nitrocellulose membrane used for Western 
blotting was Hybond ECL firom Amersham Life Sciences (Arlington Heights, 
IL). Anti-calmodulin was firom Upstate Biotech (Lake Placid, NY). The 
monoclonal y antibody, mAb88, was a generous gift firom Dr. Gerald M. 
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Carlson. [y-^zpj-ATP was purchased from ICN Biomedicals (Costa Mesa, 
CA). Phosphorylase b and tnmcated 7(1-300) were purified as previously 
described (7,10). Calmodulin was purified from bovine brain as described 
(11). 
DNA manipu/aiion-Plasmid pGPK4 (12) was digested with the 
restriction enzymes EcoRI and HindlTT to produce a 1.2 kb fragment that 
contained the coding region of the fiiU-length cataljrtic y subunit. The 1,2 kb 
y fragment was subcloned into pUCllS. The C-terminal residues 297-386 of 
the catalytic subunit, y, were isolated from pUC118-y via a Ndel-Hindlll 
restriction digest and subsequently gel purified. The new 0.6 kb PhK86 
fragment was hgated to Ndel- and HindHI digested pETlSb expression vector 
with T4 DNA Hgase. Ligation reactions were carried out at 4°C overnight. 
The nucleotide sequence of the coding region in the resulting plasmid, 
pETl5b-PhK86, was confirmed by sequencing in the Iowa State University 
DNA Facility. The expression plasmid, pET15b-PhK86 was transformed 
into E. coli strain BL21(DE3). 
Expression of PhK86-Fov expression of PhK86, E. coli BL21(DE3) 
containing pETl5b-PhK86 were cultured into 5 ml of LB broth containing 
100 M-g/ml ampicillin and grown overnight shaking at 37°C. Overnight 
cultiires were subsequently diluted 1:100 in 500 ml of LB plus ampicillin and 
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grown at either 22 °C or 37 °C with constant shaking. Cells were induced at 
an optical density (OD)6oo of either 0.6 or 0.8 with isopropyl-P-D-
thiogalactopyranoside (IPTG) at a final concentration of 0.4 mM. The 
induction of PhK86 expression proceeded for 3 hours at 37°C, or 12 hours at 
22°C. Cells were harvested by centrifugation at 5,000 x g for 10 minutes. 
Cell pellets were firozen overnight at -20 °C and used immediately. 
Purification of PhK86 Inclusion Bodies-A31 buffers utilized throughout 
the purification procedure contained protease inhibitors at the following final 
concentrations: 0.7 ng/ml pepstatin A, 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.5 ^ig/ml leupeptin, 0.2 mg/ml benzamidine, and 0.5 p-g/ml 
aprotinin. The cell pellets were resuspended in cold deionized water and 
lysed by passage through a prechilled French pressure cell two to three times 
at 5000 lb/inch psi. The resulting cell lysate was centrifuged at 12,000 x g for 
15 minutes at 4°C. The collected pellet was suspended in 20 mM Tris-HCl, 
pH 8.0. The suspension was incubated 1 hour at room temperatiire while 
shaking. Sodium deoxycholate was added to a final concentration of 1 mg/ml 
and shaking continued at room temperature for an additional hour. The 
PhK86 inclusion bodies were collected at 12,000 x g for 15 minutes at 4°C 
and suspended in 50 mM Tris-HCl pH 8.0. The final PhK86 inclusion bodies 
were dissolved in denaturing binding buffer: 5 mM imidazole, 0.5 M NaCl, 20 
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mM Tris-HCl, pH 8.0, 0.1% NP-40 and 6 M guanidine hydrochloride or 8 M 
urea, and stored at 4°C. 
Purification and Renaturation of His-tagged PhK86-Tb.e dissolved 
PhK86 inclusion bodies were filtered through a 0.45 pjn filter prior to IMAC 
purification. PhK86 inclusion bodies were loaded onto the IMAC resin and 
then washed with denaturing wash biaffer: 60 mM imidazole, 0.5 M NaCl, 20 
mM Tris-HCl, pH 8.0, 0.1% NP-40, and 6 M guanidine hydrochloride or 8 M 
urea. PhK86 was then refolded by running a continuous gradient from 
denatiiring wash buffer, containing 6 M guanidine hydrochloride or 8 M urea 
to nondenaturing wash buffer, containing no guanidine hydrochloride or urea. 
Elution of PhK86 utilized 1 M imidazole, 0.5 M NaCl, and 20 mM Tris-HCl, 
pH 8.0. Fractions collected were analyzed by SDS-PAGE for the presence of 
PhK86. Fractions containing PhK86 were pooled and dialyzed into 50 mM 
Tris-HCl, pH 7.8, 50 mM Hepes, 50 mM NaCl, with 5 mM DTT being added 
after two dialysis buffer changes. Protein concentration of eluted PhK86 was 
determined using commericially available Bradford reagents from BioRad 
(Herculues, CA). 
ImmunobloUingSamples were amalyzed by SDS-polyacrylamide gel 
electrophoresis, followed by semi-dry blotting at 36 mA for 30 minutes to 
nitrocellulose membrane. Immtinoblotting anaylsis utilized anti-calmodidin 
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or anti-y mAbSS. Proteins were detected according to the ECL protocol of 
Amersham. 
PhK86 inhibition analysis-The inhibition of truncated 7(1-300) by 
PhK86 was determined by incorporation into phosphorylase b as 
previously described with minor modification (13,14). The standard assay 
contained 50 mM Pipes, 50 mM Tris, pH 8.2, 10 mM MgCla, 4 |iM 
phosphorylase b, 5 mM DTT, ImM [y-^zpj-ATP, and 0.5 ng/ml trxmcated y(1-
300). The reaction is performed at 30°C and initiated by the addition of 
enzjrme. At specified time points 15 pi of reaction mixture was spotted on 
ET-31 Whatman filter paper, and washed with trichloroacetic acid (15). The 
radioactivity incorporated was determined by liquid scintillation coimting. 
Results 
Expression Analysis of PhK86-la the pETl5b His-tag expression 
system, a series of six consecutive histidine residues is placed N-terminal to 
PhK86. PhK86 csm be separated firom the histidine residues, if necessary, via 
a thrombin cleavage site. The histidine tag sequence enables rapid one-step 
purification by binding divalent cations, in particular Ni2+ and Co^^, 
immobilized on metal chelation resin. Expression in pET15b is under control 
of the T7 lac promoter and is induced with isopropyl-^-D 
thiogalactopyranoside. 
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Expression of PhK86 was analyzed in cells grown at 37°C (Figure 1). 
Cells were induced with 0.4mM IPTG at two different optical densities, either 
(OD)6OO of 0.6 or 0.8. High level expression of eukaryotic proteins in E. coli 
often residts in the formation of insoluble protein aggregates referred to as 
inclusion bodies. PhK86 can be seen in the cell peUet when induced at 37°C. 
Reduction in growth temperatxire can result in soluble expression. Therefore, 
we additionally examined PhK86 expression at 22°C (Figure 2). PhK86 can 
be foimd in the insoluble inclusion body pellet regardless of temperature or 
ceU density upon induction. 
Renaturation of PhK86-lnclusion bodies can offer high jdeld and 
relatively easy purification for proteins of interest. PhK86 inclusion bodies 
were purified as described in experimental procedures. After dissolving the 
PhK86 inclusion bodies in denaturing buffer, and subjecting the sample to 
immobilized metal affinity chromatography, PhK86 was eluted in denaturing 
buffer. Initial trials on refolding PhK86 utilized a procedure previously 
successful in our laboratory for refolding truncated 7(1-300). This method 
involves dilution of PhK86 to 10 fig/ml, followed by overnight incubation at 
4°C. Unfortunately, all detectable PhK86 precipitated during this procedure 
(data not shown). The next attempted procedure involved eluting PhK86 in 
denatiiring buffer and subjecting PhK86 to the step-wise removal of guanidine 
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or xirea via dialysis. Each dialysis buffer change reduced the amount of 
guanidine or virea present. PhK86 precipitated in this procedure after 
removal from IM guanidine or urea (data not shown). The third attempt to 
renature PhK86 utilized the metal ion affinity resin to immobilize PhK86. It 
has been suggested that immobilizing the protein may limit protein-protein 
interaction and help limit aggregation (16). PhK86 was bound to the metal 
affinity resin in denaturing buffer. Next a gradient was nm from denaturing 
buffer to non-denaturing buffer in 80 column volumes. A sample of renatxired 
immobilized-PhK86 can be seen in Figure 3. 
Functional Analysis of PhK86-We believed that PhK86 had been 
successfrdly renatured. However, PhK86 lacks a detectable enzjonatic 
activity to test whether refolding was successful. Thus, we turn to an 
alternative assessment of functionality. Samples of PhK86 bound to the 
metal affinity resin were incubated with calmodulin in the presence and 
absence of calcium and EGTA, as a suspension (Figure 4). No detectable 
calmodulin boxmd to the metal affijiity resin itself. Immobilized-PhK86 
bound calmodulin. A second test for functionality including the binding of 
truncated Y(1-300) to immobilized-PhK86 (Figure 5). Truncated Y(1-300) did 
bind to the metal affinity resin under the current conditions used. The signal 
produced in the immobilized-PhK86 +truncated 7(1-300) lane is 
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approximately two fold stronger, indicating that PhK86 did bind tnincated 
y(l-300). 
Elution of PhKSGStrixctvxal studies of PhK86 will need large amounts 
of refolded, soluble protein. Figure 6 illustrates the protein elution profile for 
PhK86 from the metal affinity resin as detected by Bradford. This profile is 
from 4 ml PhK86 inclusion body sample at 2 mg/ml nm over a 1 ml metal 
affinity column. All fractions collected were analyzed by SDS-PAGE for the 
presence of PhK86 (Figure 7). Fractions containing PhK86 were pooled and 
dialyzed to remove the imidazole. The concentration of PhK86 obtained from 
this small column was 6 jiM. We are confident that higher yields of PhK86 
can be obtained from scaling this procedure up to a larger sample volxime. 
PhK86 Inhibition of truncated y(l-300)-V\iKSQ contains both PhKl3 
and PhK5, two inhibitory regions of the catalj^ic y subunit of phosphorylase 
kinase. Eluted PhK86 was analyzed as an inhibitor of truncated y(1-300), 
with respect to phosphorylase b as substrate. Although only a relatively 
small concentration of PhK86 was available for testing, PhK86 inhibited 
trimcated 7(1-300) (Figure 8). 
Discussion 
The protein kinase activity of many members of the calcium, 
calmodulin-dependent protein kinase family, of which phosphorylase kinase 
86 
is a member, may be regulated by intrasteric regulation. The C-terminus, 
PhK86, of the catalytic y subxanit of phosphorylase kinase comprises two non­
contiguous autoinhibitory calmodulin binding domains, PhK13 and PhK5. 
Structurally, it is unknown how the C-terminus of the y catalytic subunit 
interacts with its kinase core, or the other subimits, a, P and 5, found in 
holoenzyme, to regulate activity. Attempts to produce full-length y(l-386) for 
structural studies have been unsuccessful. Thus, an alternative approach was 
to express PhK86. 
Two possible modes of binding are possible for PhK86. PhK86 could 
bind directly to the active site blocking access of substrate, phosphorylase b. 
Data supporting this possibility comes from peptide studies utilizing PhK13, 
a segment of PhK86. PhKlS and a shorter version, PhK13-l are competitive 
inhibitors of truncated y(l-300), with respect to phosphorylase b (Bartleson, 
unpublished data)(17). Indirect evidence comes from the differential 
inhibition of PhK5. PhK5 is a non-competitive inhibitor of truncated y(l-300), 
yet, PhK5 competitively inhibits holoenzjnne phosphorylase kinase, with 
respect to phosphorylase b (17,18). Precedence for this mode of binding is 
illustrated by the crystal structmre of twitchin kinase (19). The C-terminal 
autoinhibitory domain of twitchin traverses the active site. The second 
possibility is that PhK86 binds outside of the active site but that the binding 
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of PhK86 influences the binding of substrate in the active site. The crystal 
structure of calmodulin-dependent protein kinase I indicates that this may be 
the mode of inhibition for this kinase (20). Recent small angle X-ray and 
neutron scattering studies indicate that this may also be the mode of 
inhibition for myosin light chain kinase (21,22). The C-terminal domains of 
calmodulin-dependent protein kinase I and myosin light chain kinase do not 
traverse the active site but form multiple contacts with the kinase catalytic 
core. In order to test these models of interaction in phosphorylase kinase, an 
unproteolyzed, intact regulatory domain, PhK86, must be generated. 
We have successfully expressed PhK86 as a histidine tagged fusion 
protein in E. coli. Soluble expression of PhK86 was not observed under 
conditions tested. PhK86 is expressed as an inclusion body. Inclusion bodies 
can provide an abundant, relatively pxire source of protein. A refolding 
protocol has been developed that involves refolding PhK86 while immobilized 
on the metal affinity resin, in an effort to minimize protein-protein 
interactions that can result in aggregation. Renatxiration of PhK86 employs 
the use of a continuous gradient that reduces the presence of denatiirant. 
One caveat of working with renatured proteins can be in testing if the 
refolded product has been properly renatured. Often, enzymatic activity can 
be utilized as a reasonable indicator. PhK86 lacks a testable enzymatic 
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activity. This led us to utilize an alternative method to ascertain whether 
PhK86 was properly renatured. Functionality of PhK86 was examined 
through the ability of calmodulin to bind to renatured, immobilized PhK86. 
Western analysis with anti-calmodiilin demonstrates calmodulin binding to 
PhK86. Calmodvdin boimd PhK86 in the absence of added calcium. However, 
the binding of calmodulin to PhK86 was enhanced upon the addition of 
calcixmi. In the sample lacking PhK86, we were xmable to detect calmodulin, 
indicating that the PhK86 was necessary for the interaction with calmodulin. 
A second test of functionality involved checking the ability of truncated Y(1-
300) to bind to renatured, immobilized PhK86. Western analysis with anti-y 
indicates truncated 7(1-300) binding to PhK86. Non-specific binding of 
truncated y(1-300) to the IMAC resin was observed imder the conditions 
utilized. Experimental conditions will be adjxisted in an effort to reduce the 
interaction of tnmcated y(1-300) with the IMAC resin. 
Initial results with eluted, soluble PhK86 indicates that PhK86 
inhibits truncated 7(1-300). Work is in progress to scale up the expression 
and increase the 3deld of PhK86, in order to generate amoimts suf&cient for 
structiaral studies. 
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Figure 1. SDS-PAGE analysis of PhK86 eypressian @37° C. 
A) total protein control, pETlSb; 
B-D) total protein PhK86; 
E) supernatant PhK86; 
F-G) inclusion body PI1K86; 
H) final PhK86 inclusion body solublized in guanidine. 
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Figure 2. SDS-PAGE analysis of PhK86 expression @ 22 °C. 
Panel A) 
A) OD 0.8 pETlSb supernatant 
B) OD 0.8 pET15b-PhK86 supernatant 
C) OD 0.6 pET 15b-PhK86 supernatant 
MW) Gibco prestained molecular weight markers 
D) OD 0.8 pETb supernatant + EMAC resin 
E-F) OD 0.6 pET 15b-PhK86 supernatant + IMAC 
Panel B) 
A) OD 0.8 pETlSb pellet + EMAC resin 
B) OD 0.6 pET15b-resin 
C) OD 0.8 pET15b-PhK86 pellet + IMAC-resin 
MW) Gibco prestained molecxilar weight markers 
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Figure 2 (continued) 
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Figure 3. SDS-P AGE Analysis of Refolded PhK86. 
A) refolded PhK86, 14.9 kDa from the metal affinity colimm 
MW) Gibco prestained molecvilar weight markers 
Figure 4: Western analysis of calmodulin binding to PhK86. 
A) PhK86 + calmodulin + calcixmi; 
B) PI1K86 + calmodulin; 
C) PhK86 + calmodulin -1- 0.2 mM calcium+ 2 mM EGTA; 
D) PhK86 +calmodulin + 2mM EGTA; 
E) PhK86 
F) Calmodulin 
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Figure 5: Western analysis of truncated y 1-300 binding to PhK86. 
A) IMAC-resin+PhK86; 
B-C) IMAC-resin + truncated y 1-300; 
D-E) IMAC-resin+PhK86 + truncated y 1-300. Anti-y antibody 
was a generous gift from Dr. Gerald Carlson. Note: under the 
experimental conditions used, non-specific binding of truncated 
y(l-300) to the IMAC-resin was observed. 
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Figvire 6. Elution profile of PhK86 from IMAC chromatography. 
Protein concentration in individual fractions was 
determined by Bradford assay described in 
experimental procedures. 
Figxire 7: SDS-PAGE Analysis of Eluted PhK86. 
A) Fraction number 4 
B) Fraction number 6 
C) Fraction number 8 
D) Fraction number 10 
E) Fraction number 12 
MW) Gibco prestained molecular weight markers 
F) Pooled, dialyzed PhK86 sample 
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Figure 8. Initial time course of truncated y(1-300) inhibition by PhK86. 
Ix PhK86 is equivalent to 1 |iM PhK86 and 2x PhK86 is 
equivalent to 2 |iM PI1K86. Substrate was phosphorylase h. 
Assay conditions as described in experimental procedures 
with n=3. 
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MUTANTS OF PHOSPHORYLASE-a ALTERED IN 
RECOGNITION BY PROTEIN PHOSPHATASE ! 
A paper to be submitted to the Journal of Biological Chemistry 
Cheryl Bartleson, Alyssa C. Biom, and Donald J. Graves 
Abstract 
Little information is known about the substrate specificity of protein 
phosphatase-1. The success obtained studying protein kinase substrate 
specificity with peptide substrates has not extended to protein phosphatases. 
Protein phosphatases are believed to recognize higher order structure in 
substrates in addition to the primary sequence surrovmding the 
phosphoserine or threonine. Peptide studies have revealed a preference for 
basic residues N-terminal to the phosphoserine. Studies suggest that 
arginine 16 in phosphorylase a may be a positive determinant. 
In order to develop our knowledge of specificity determinants for protein 
phosphatase-1, mutants of phosphorylase b have been converted to their 
corresponding phosphorylase a and examined for their efficacy as substrates 
for protein phosphoatase-1. Mutants focused on the N-terminal primary 
sequence surrounding the phosphoserine. R16A, R16E, and I13G 
phosphorylase b mutants were generated and converted to phosphorylase a 
using phosphorylase kinase. 
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Protein phosphatase-1 prefers the positive charge on arginine 16. 
R16A-a exhibits a similar Km but reduced Vmax, and R16E-a has an increased 
Km and a decreased Vmax, when compared to phosphorylase a. I13G-a has a 
similar Km but an increased Vmax. Surprisingly, I13G-a has no phosphorylase 
a activity in the absence of AMP. Thus, I13G-a is the first reported mutant of 
phosphorylase that is not activated by phosphorylation. Additional resvdts 
with this mutant reveals that I13G-a may actually be more phosphorylase b 
like in its properties. 
Introduction 
Protein phosphatase-1 is one of four major serine/threonine 
phosphatases identified by substrate specificity and susceptibility to specific 
inhibitors (1). These phosphatases are designated as phosphatases type-1, -
2A, -2B, also known as calcineurin, and -2C. Protein phosphatase-1, PP-1, is 
considered a broad specificity phosphatase. However, the best known 
physiological protein substrate for protein phosphatase-1, is phosphorylase a 
(2). Little information is available on the specificity of protein phosphatase-
1. The wealth of knowledge of protein kinase specificity derived firom peptide 
studies has not extended to the protein phosphatases. This could be due to 
the fact that phosphopeptides are not very good substrates for many 
phosphatases (3). Protein phosphatases seem to be less dependent on 
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primary structure and more dependent on aspects of secondary structure for 
recognition of substrate. 
Some information has been gained &om phosphopeptide studies. The 
preference for basic residues N-terminal to the phosphoserine was found to be 
a general determinant for protein phosphatase-1 (3). An additional potential 
preference for a basic residue C-terminal to the phosphoserine might exist. 
Peptides derived from phosphorylase a lacking the residue arginine 16 fail to 
function as protein phosphatase-1 substrates (4). Modification of arginine 16 
in peptide substrates by nitrosylation, and amidation, and more recently 
through substitution to citniUine indicates that a positive charge may be 
important for substrate recognition (5,6). Analysis of the citruUine 
substituted peptides substrates indicated that arginine 16 was important for 
enhanced tmrnover (6). Many interactions occur in the stabilization of the N-
terminal region of phosphorylase a (7). NMR studies show an interaction of 
arginine 16 with the phosphoserine in peptide substrate (6). The crystal 
structure of phosphorylase a shows the phosphoserine complexed with 
arginine 69 and arginine 43', an arginine present in the neighboring 
phosphorylase (7). All of these interactions may contribute to the overall 
specificity of protein phosphatase-1. 
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Limited knowledge has been gained &om mutagenesis experiments 
involving protein phosphatase-1. The acidic groove, proposed to bind the N-
terminal basic residues found in many protein phosphatase-1 substrates, was 
extensively mutated. No major changes in the kinetic parameters for 
phosphorylase a were observed. The systematic mutagenesis involved 
changing one amino acid at a time, and this might have led to some 
compensation in the mutants by the surrounding acidic residues still 
available (8). 
Phosphorylase mutants were constructed to examine the specificity of 
protein phosphatase-1 using a physiologically relevant protein substrate. The 
selected mutants change the primary structure around the phosphorylatable 
site in the N-terminus of phosphorylase b. The basic residue foimd at the P+2 
position of phosphorylase was changed to R16A and R16E respectively. This 
arginine residue is a positive specificity determinant for phosphorylase 
kinase, and is a potential positive determinant for protein phosphatase-1. A 
hydrophobic residue in position P-1 was changed to glycine, I13G. Isoleucine 
is involved in the formation of the 3io helical segment found in phosphorylase 
a. Incorporation of glycine into peptide substrates of phosphorylase kinase 
had a large detrimental effect on phosphorylation (9). Substituting glycine 
may disrupt the helical structure and make this region more conformationally 
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flexible. All mutant phosphorylase a's were compared to wild-type-a with 
respect to substrate recognition by protein phosphatase-1. 
Experimental procedures 
Materials. All chemicals were commercially available from Boehringer 
Mannheim (Indianapolis, IN), Fisher (Pittsburgh, PA), or Sigma (St. Louis, 
MO). The trxmcated cataljrtic y subunit of phosphorylase kinase was 
renatured as described (10). Recombinant protein phosphatase-1, (PP-1), was 
purchased from New England Biolabs (Beverly, MA). Alkedine phosphatase, 
(AP), was available from Sigma. Calcineurin, (CaN), was a generous gift of 
Dr. Bruce L. Martin. Protein phosphatase-2A, (PP2A), was purchased from 
Upstate Biotechnology (Lake Placid, NY). [y-32P]ATP was from ICN 
Biomedicals (Costa Mesa, CA). 
Preparation of Wild-type and Mutant Phosphorylase b. Wild-type 
phosphorylase was purified as described (11). Oligonucleotides used in site-
directed mutagenesis were synthesized in the Iowa State University DNA 
Facility. Phosphorylase mutant R16A was generated by single-stranded 
mutagenesis using the Kxinkel method (12). Phosphorylase mutants R16E, 
and I13G was generated by double stranded mutagenesis using the Qmck 
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Change Site-Directed Mutagenesis Kit from Stratagene (LaJoUa, CA). 
Recombinant phosphorylases were expressed and p\iri&ed as described (13). 
Preparation of Wild-type and Mutant Phosphorylase a. Wild-t3rpe and 
the individual mutant phosphorylase b's were converted to phosphorylase a as 
described by Krebs and Fischer, with some modification (14). Tnincated 7(1-
300) was used with 1 mM [y-^zpjATP, 10 mM MgCla, 5 mM dithiothreitol, 50 
mM Pipes, and 50 mM Tris, pH 8.2. At a specified time, sample aliquots 
were removed firom the reactions and spotted on ET-31 Whatman filter paper. 
Samples were washed and counted to determine the amoimt of radioactivity 
incorporated into phosphorylase a (15). Phosphorylase a activity was 
measured in the presence and absence of AMP as described (16). 32p. 
phosphorylase a's were dialyzed into 50 mM imidazole, pH7.2, 5 mM 
dithiothreitol and stored at A°C. 
Protein Concentration Determinations. Protein concentrations of wild-
type and mutant phosphorylases were determined spectrophotometrically at 
280 nm (17). 
Circular dichroism. The circular dichroism spectra of wild-type 
phosphorylase b and a, and I13G b and a was determined in the Iowa State 
University Protein Facility using a Jasco J-710 spectropolarimeter (Jasco 
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Corporation, Tokyo, Japan). Samples were diluted in 10 mM phosphate 
buffer, pH 6.8. Phosphorylase was diluted to 0.1 mg/ml for the analysis. 
The wavelength scan was rxm from 200 to 260 nm utilizing a 0.1 cm cell. 
Analytical ultracentrifugation. Equihbrium velocity centrifugation of 
wild-tjrpe phosphorylase b and a, and I13G b and a was performed in the Iowa 
State University Protein Facility using a model XL-A Maxima Optima 
Beckman centrifuge. Data was analyzed with Beckman XL-A software. 
Samples were in 40 mM P-glycerol phosphate, pH 6.8, 100 mM KCl. 
Assays of protein phosphatase activities. PP-1 assays were performed as 
previously described (18). The final assay mixture of 0.1 ml, contained 0.2 
mg/ml p2-P]phosphorylase a, 50 mM imidazole, pH 7.2, 2mM dithiothreitol, 
0.5 mg/ml bovine serum albumin, 5 mM caffeine, 0.2 mM MnCla. Alkaline 
phosphatase assays were performed at 30°C. The 0.1 ml reactions contained 
25 mM Tris, pH 8.0, ImM MgCh, 0.2 mg/ml [32-P]phosphorylase a, 2mM 
dithiothreitol, 0.5 mg/ml bovine serxmi albimiin, 5 mM caffeine. The reaction 
conditions used for protein phosphatase-2A were the same as for protein 
phosphatase-1. Assays with calcineurin contained 25 mM Mops, pH 7.0, 1 
mM MnCl2, 10 jig/ml calmodulin, 0.1 mM CaCb, 2 mM dithiothreitol, 0.5 
mg/ml bovine senun albumin, 5 mM caffeine, and 0.2 mg/ml 
[32p]phosphorylase a. Reactions were started with the addition of the 
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specified protein phosphatase. Samples were incubated at 30®C for 5 to 20 
minutes. Reactions were terminated by the addition of 10 |il of 100% 
trichloroacetic acid. Samples were microcentrifuged for 10 minutes to 
precipitate protein. 50 |il of supernatant was spotted into 10 ml of 
scintillation cocktail and coimted to determine the pmol P^P] released. 
Kinetic data were analyzed with Enzyme Kinetics (Trinity Software). 
Phosphorylase-a concentrations varied from 0.4 up to 18 jiM depending 
on the mutant phosphorylase a utilized. 
Results 
Phosphorylase a Activities in the presence and absence of AMP. Wild-type 
phosphorylase a and R16A-a, R16E-a, and I13G-a activities were assayed in 
the presence and absence of AMP. After phosphorylation, the activity of 
phosphorylase a in the absence of AMP should be equivalent to the activity in 
the presence of AMP. Do the mutant phosphorylase a's exhibit similar 
activities compared to wild-type-a? As shown in Figure 1, wild-ts^pe-a, R16A-
a, and R16E-a all exhibit similar activities +/- AMP. Interestingly, I13G-a 
has no detectable activity in the absence of AMP. 
CD spectra of wild-type-a compared to I13G-a. The lack of activity observed in 
I13G-a after phosphorylation, led us to examine the secondary structure of 
this phosphorylase compared to wild-type-a. The N-terminal 
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phosphorylatable region in phosphorylase ^ residues 10-18,appears to be in a 
random conformation (7). Upon phosphorylation, the N-terminus of 
phosphorylase a moves, rotates up, and interacts at the subunit interface, 
with a 3io helix forming aroxmd the phosphorylatable serine (7). Figure 2, 
panel A illustrates the CD spectra of wild-type-b, compared with I13G-b. The 
secondary structures of these two proteins are almost identical. The 
secondary structures of wild-type-a and I13G-a are compared in Figure 2, 
panel B, respectively. The secondary structures of the phosphorylated wild-
type-a and I13G-a are again very similar, indicating that a change in 
secondary structure has occurred in I13G-a upon phosphorylation. However, 
this secondary change did not result in activation of phosphorylase. 
Analytical ultracentrifugation. The quaternary structures of wild-type-
b, and-a were compared to I13G-b and -a using equilibrium velocity 
centrifugation. Wild-type-b exists as a dimer and wild-type-a forms a 
tetramer. The results are illustrated in Figure 3, panels A and B. Figure 4, 
panel A shows that I13G-b exists as a dimer. Panel B of Figure 4 
demonstrates that I13G-a does not form a tetramer, but remains a dimer. 
The calculated molecvdar weight for I13G-b was 215,430 Da, and I13G-a was 
197,050 Da. 
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AMP activation curves of wild-type-a and I13G-a. Phosphoiylase b can 
be activated allosterically by AMP. Phosphorylase b cooperatively binds 
AMP, while phosphorylase a does not (19). H3G-a has no activity after 
phosphorylation. Thus, it is possible that I13G-a might be similar to wild-
type-b. The AMP binding cvirves of wild-type-a and I13G-a are shown in figure 
5. Figure 6 shows I13G-b and I13G-a. The AMP binding of I13G-a appears to 
be more like wild-type-b. 
Effect of Glucose-1-phosphate, GlP, on the activity ofI13G-a. The classic 
model of cooperativity is based on the existence of multiple conformational 
states, ranging from a T state, low affinity, to an R state, with high affinity for 
substrate. Wild-type-b has a Km of 50 mM for glucose-1-phosphate, whereas 
wild-type-a has a Km of 3.8 mM (20). Figure 7 illustrates the activities of 
wild-type-b and I13G-b compared to wild-type-a and I13G-a in the presence of 
increasing amounts of glucose-1-phosphate, in the absence of AMP. Both 
wild-type-b and I13G-b exhibit increased activities with increased glucose-1-
phosphate. No activity was detected in any of the 113G-a samples. I13G-a 
appears to more T state than R state. 
Dephosphorylation of wild-type and mutant phosphorylase a's with PP-1. 
Dephosphorylation of wild-type-a was compared to dephosphorylation of the 
mutants R16A-^ R16E-a, and I13G-a using protein phosphatase-1. The 
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residts of the time courses can be seen in Figure 8. Protein phosphatase-1 
dephosphorylated all of the phosphorylase a's to varying extents. R16E-a was 
dephosphorylated at the lowest rate. R16A-a was dephosphorylated at a rate 
approximately one-half that of wild-type phosphorylase a, while I13G-a was 
dephosphorylated at a faster initial rate. 
Comparison of dephosphorylation of wild-type-a and mutant 
phosphorylases with different protein phosphatases. Figure 9 illustrates the 
differences in dephosphorylation for wild-type-a, R16A-a, R16E-a, and I13G-a 
with protein phosphatase-1, protein phosphatase 2-A, alkaline phosphatase, 
and calcineurin. Consistent with the time course of dephosphorylation 
presented in Figure 8, protein phosphatase-1 dephosphorylated all of the 
phosphorylase a's to different extents. Rl6E-a was the least preferred 
substrate for protein phosphatase-1. R16A-a was dephosphorylated at a rate 
about 50% compared to wild-type-a. I13G-a was actually a better substrate 
than wild-type-a. Protein phosphatse -2A dephosphorylatd wild-type-a and 
R16A-a equally, and preferred R16E-a the least. I13G-a was again preferred. 
Although I13G-a was much preferred by protein phosphatase 2-A, compared 
to wild-type-a, 63% versus 21%. Calcineurin followed the same substrate 
preference pattern of protein phosphatase 2-A, albeit to a lesser extent for 
I13G-a. No significant dephosphorylation of wild-type-a or any mutant, 
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R16A-a, Rl6E-a or I13G-a, was detected using alkaline phosphatase. More 
units of the other protein phosphatases, protein phosphatase-2A , calcineurin, 
and alkaline phosphatase were used than units of protein phosphatase-l. 
Kinetic analyses of wild-type-a and mutant-q^s with PP-1. Table I 
contains a summary of the kinetic analyses for dephosphorylation of wild-
type-a compared with R16A-a, R16E-a, and I13G-a using protein 
phosphatase-1. All experiments were run with using equivalent phosphate to 
determine the concentration of phosphorylase a mutants that were not 100% 
phosphorylated. The Km for I13G-a was similar to the Km for wild-type-a, 
although the Vmax was 2 fold greater for I13G-a than that for wild-type-a. 
R16E-^exhibited approximately a 3 fold increase in Km, and a 6.5 fold 
decrease in Vmax. R16A-a had a similar Km to wild-type a, but had a 3.3 fold 
lower Vmax. 
Discussion 
We were interested in addressing the structural basis for recognition of 
phosphorylase a by specific phosphatases, protein phosphatase-1 in 
particular. What makes the dephosphorylation reaction much more efiective 
with protein substrate compared to phosphopeptide substrate? Why do some 
phosphatase, alkaline phosphatase for example, dephosphorylate phospho-9-
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18 peptide, but do not dephosphorylate phosphorylase a? Mutants of 
phosphorylase a were made to address this question of specificity. 
The phosphorylase a mutants, R16A-a and R16E-a were active in the 
presence of AMP, as well as in the absence of AMP after phosphorylation. 
Both mutants exhibited activities very similar to wild-tjrpe-a. Although I13G-
a shows activity similar to wild-type-a in the presence of AMP, we were 
unable to detect any phosphorylase a activity in the absence of AMP after 
phosphorylation. 
The lack of I13G-a activity after phosphorylation led to some further 
characterization of I13G-a compared to wild-t3rpe-b £md wild-type-a. In the 
crystal structure of phosphorylase b, the N-terminus, containing the 
phosphorylatable serine, forms a random structure (7). After 
phosphorylation, the structure of the N-terminus changes to a 3io helix, and 
rotates up to the subunit interface (7). Although we can not detect such 
conformational changes, the absence of activity in I13G-a suggests that a 
change in conformation has occurred. The CD spectra indicate that the overall 
secondary structure of I13G-b and I13G-a do not differ significantly from wild-
type-b and wild-tj^pe-a. The conformational change occurring upon 
phosphorylation of I13G-a, is not the same change that occurs in wild-type-a. 
This is evident from the lack of I13G-a activity after phosphorylation. 
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The quaternary structure of phosphorylase b is a dimer. Wild-type-a 
forms a tetramer. The molecular weight of the phosphorylase monomer is 
97,500 Da, the dimer is 195,000 Da, and the tetramer is 390,000 Da. I13G-b 
has an average molecular weight of 215,430 Da, and I13G-a has an average 
molecular weight of 197,050 Da. The results &om equilibrium velocity 
centrifiigation indicate that I13G-a is a dimer. From this data it appears 
that I13G-a is more like wild-type-b. 
Additional support for I13G-a being similar to wild-type-b comes from 
the AMP activation curves. The apparent cooperativity that I13G-a exhibits 
is consistent with I13G-a behaving more like wild-tjrpe-b. The T state, low 
affinity, of phosphorylase b has a high Km for glucose-1-phosphate, while the R 
state, high affinity, of phosphorylase a has a much reduced Km for glucose-1-
phosphate. When the activities of wild-type-b, and wild-type-a, are compared 
to the activities of I13G-b and I13G-a in the presence of increasing amounts of 
glucose-1-phosphate, but lacking AMP, I13G-a exhibits no activity. This 
resxilt is consistent with I13G-a being similar to the T state, like 
phosphorylase b. 
The similarity in the Km for I13G-a, compared to wild-type-a indicates 
that protein phosphatase-1 recognizes similar features common to both of 
these conformations of phosphorylase a. The increased Vmax might translate 
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to a more accessible phosphoserine residue. Increased accessibility of the 
phosphoserine residue could explain why I13G-a was dephosphorylated to a 
greater extent by protein phosphatase-2A and calcineurin. Alternatively, the 
substitution of isoleucine with glycine into the N-terminus of phosphorylase b 
could disrupt the ability of the N-terminus to form a 3io helix and dock at the 
subxmit interface. This potential alternative conformation may be more 
favorable for dephosphorylation. 
Substitution of Rl6 with citruUine in peptide substrate derivatives of 
9-18, a peptide of the phosphorylatable region of phosphorylase b, resulted in 
decreased dephosphorylation of this peptide by protein phosphatase-1 (6). It 
was suggested that R16 either enhances substrate turnover for protein 
phosphatase-1, or alternatively, that protein phosphatase-1 recognizes the 
complex formed from the interaction of arginine with the target 
phosphoserine. This interaction could be with arginine 16. Alternatively, this 
interaction might occur with residues arginine 69 and arginine 43' in 
phosphoiylase a. 
Our results confirm the importance of arginine 16 for phosphorylase a 
recognition by protein phosphatase-1. Both of the R16 phosphorylase-a 
mutants, R16A-a and R16E-a were dephosphorylated by protein 
phosphatase-1 at a lesser rate. The Km and Vma* for R16E change 
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significantly. Rl6A-a has a similar Km compared to wild-type-a, but the Vmax 
decreases. It appears that protein phosphatase-1 does prefer the positive 
charge of arginine 16 for optimal turnover, but it will dephosphorylate the 
R16A-a and R16E-a mutants. Alkaline phosphatase was able to 
dephosphorylate the citrulline substituted phosphopeptides of phosphorylase 
a (6), yet we were unable to detect any significant dephosphorylation of 
phosphorylase a or any of the mutants with alkaline phosphatase. These 
results again emphasize protein phosphatase specificity for higher order 
structure in addition to the primary structiire. Further work involving 
mutagenesis of phosphorylase a, as weU as other physiologically relevant 
protein phosphatase substrates is warranted. The combination of available 
crystal structures of phosphorylase a with the crystal structure of protein 
phosphatase-1 should help guide the planning of future experiments. 
Additional experiments with phosphoprotein substrates of protein 
phosphatases will help broaden our understanding of protein phosphatase 
substrate specificity. 
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R16A R16E I13G 
Figure 1. Phosphorylaseji activites in the presence and absence of AMP. 
Assay conditions are described under experimental procedures. 
The concentration of AMP is ImM. 
Figure 2. Circular dichroism spectra of wild-type phosphorylase and I13G 
phosphorylase. 
Panel A: Spectra of wild-type-b compared to I13G-b. 
Panel B: Spectra of wild-type-a compared to H3G-a. 
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Figure 2 continued 
Figure 3. Analytical ultracentrifugation results for wild-type-^ and wild-
type-q.. 
Experimental procedures are decribed in the methods. Panel 
A is wild-type-b. Panel B is wild-type-a. 
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Figure 3 continued 
Figure 4. Analytical ultracentrifugatioTt results for I13G-b and IlSG-q.. 
Experimental procedures are decribed in the methods. Panel 
A is I13G-b. Panel B is I13G-a. 
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Figure 4 continued 
Figure 5. AMP activation curves of u)ild-type-b and wild-type-a. 
Assay conditions described in Experimental procedures. 
Wild-type-b and wild-type-a in the presence of increasing 
amounts of AMP. 
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Figure 6. AMP activation curves of I13G-b and I13G-q. 
Assay conditions described in Experimental procedures. 
I13G-b and I13G-a in the presence of increasing 
amounts of AMP. 
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Figure 7. Effect of glucose-l-phosphate on wild-type and I13G 
phosphorylases. 
Panel A shows wild-type-b and I13G-b in the presence of 
increasing glucose-l-phosphate concentrations. Panel B 
shows wild-type-a and I13G-a in the presence of increasing 
glucose-l-phosphate concentrations. All assay were in the 
absence of AMP. Assay described in experimental 
procedures. 
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Figxire 8. Dephosphorylation of wild-type-Qj R16A-Q, 
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phosphatase-1. Assay conditions are described 
in experimental procedures. 
141 
160 n 
140-
120-
PP-1 PP-2A AP CaN 
• wt 
• R16A 
• R16E 
• I13G 
Figure 9. Comparison of dephosphorylation of wild-type and mutant 
phosphorylases with different protein phosphatases. 
Assay conditions used for each protein phosphatase are 
described in experimental procedures. 
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Table I Kinetic Constants for Phosphorylase a Mutants with Protein 
Phosphatase-1 
Km (jiM) Vmax (nmol P/min/mg) 
wild-type-a 0.94 + 0.05 5124 + 600 
R16A-a 1.46 + 0.3 1533 + 200 
R16E-a 3.4 + 0.3 778 + 150 
I13G-a 1.0 + 0.14 13,208 + 1,500 
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GENERAL CONCLUSIONS 
Many crucial cellular processes are regulated by conformational 
changes that result &om reversible phosphorylation of specific serine, 
threonine, or tyrosine residues. Control by phosphorylation is achieved by 
protein kinases and protein phosphatases that catalyze the opposing 
phosphorylation and dephosphorylation reactions, respectively. Protein 
phosphorylation and dephosphorylation were discovered in 1955 with glycogen 
phosphorylase (112,113). 
Phosphorylase kinase is a key enzyme involved in control of glycogen 
metaboUsm. Phosphorylase kinase catalyzes the phosphorylation of glycogen 
phosphorylase converting phosphorylase fi*om its inactive b form, to the active 
a form. Glycogen phosphorylase is the only recognized substrate of 
phosphorylase kinase in vivo. One aim of this research was to understand the 
specificity of phosphorylase kinase for phosphorylase. Peptide studies have 
jdelded a wealth of information about the specificity determinants for many 
protein kinases. Peptides of the phosphorylatable region of phosphorylase b 
are effective substrates of phosphorylsise kinase (67). It was previously 
estabhshed that phosphorylase kinase prefers basic residues N-terminal to 
the phosphorylatable serine residue 14 (67-69). It has been suggested that a 
basic residue C-terminal to the phosphorylatable serine might be an 
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additional specificity determinant for phosphorylase kinase recognition of 
phosphorylase. Peptide studies utilizing arginine to citruUine substitutions 
for the C-terminal arginine, R16Cit, and for both the C-terminal and N-
terminal arginines, R16Cit and RlOCit, were synthesized. Phosphorylation 
of the citndline peptides was poor. These resxilts suggest that arginine 16 is 
important for the recognition and effective phosphorylation of phosphorylase 
by phosphorylase kinase. The fact that citruUine is similar in size to arginine 
implies that charge is the critical requirement at position 16. Work in 
progress in the lab on arginine 16 mutants of phosphorylase will help expand 
our imderstanding of phosphorylase kinase recognition of phosphorylase. 
Phosphorylase kinase is a member of the calcium-calmodulin regulated 
protein kinase family. The catal3rtic activity of these protein kinases appears 
to be regulated intrasterically by autoinhibitory domains in their C-termini 
(76). The C-terminus of phosphorylase kinase, PhK86, contains two non­
contiguous autoinhibitory regions, PhKl3 and PhK5. Peptides of these 
regions are competitive inhibitors of phosphorylase kinase (70,114). This 
suggested that PhK13 could bind to the active site of phosphorylase kinase 
and might function as a pseudosubstrate inhibitor. In this work, variants of 
PhK13 were prepared to localize the determinants for interaction with 
phosphorylase kinase. All of the residues necessary for inhibition of 
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phosphorylase kinase are located in the N-terminal half of PhK13, peptide 
PhK13-l. Substitution of residue cysteine 308 with serine indicates that this 
cysteine residue is important for the inhibition of phosphorylase kinase. 
PhKl3-l is a potent competitive inhibitor of phosphorylase kinase with 
respect to phosphorylase b phosphorylation and ATPase activity. Although 
PhK13-l does not appear to function as a pseudosubstrate, several specificity 
determinants employed in the recognition of phosphorylase b as substrate 
seem to be utilized in the recognition of PhKl3-l as an inhibitor. 
The crystal structure of a truncated form, residues 1-298, of the 
catalytic sub unit of phosphorylase kinase has been solved (57). No structural 
information is available on the C-terminus, PhK86, residues 297-386, of the 
catalytic subunit of phosphorylase kinase. Expression of PhK86 as a 
histidine-tagged fusion protein in E. coli resulted in formation of insoluble 
inclusion bodies. A piudfication and renatxiration protocol was developed that 
will lead to successful production of amounts of PhK86 suitable for future 
structure/function analyses. 
Another key enzyme involve in control of glycogen metabolism is 
protein phosphatase-1. Protein phosphatase-1 catalyzes the 
dephosphorylation of phosphorylase a, active, to yield phosphorylase b, 
inactive. Phosphorylase a is the best and most commonly used substrate for 
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protein phosphatase-1 (94). Much less is known about the specificity of 
protein phosphatase-1. The success obtained studjdng protein kinase 
substrate specificity with peptide substrates has not extended to protein 
phosphatases. Protein phosphatases seem to recognize higher order structure 
in substrates in addition to the primary sequence surrounding the 
phosphoserine/threonine residue. Basic residues N-terminal to the 
phosphoserine seem to be a general determinant (106). Other studies 
suggested that arginine 16 might be important for protein phosphatase-1 
recognition of phosphorylase a (104,105,107). Mutations focused around the 
phosphoserine residue of phosphorylase were studied with protein 
phosphatase-1. Recognition of the mutant, I13G was altered. No detectable 
activity was observed in this mutant after phosphorylation. Characterization 
of I13G resulted in the conclusion that this mutant may be more 
phosphorylase b like in its properties. Results with the arginine 16 mutants 
of phosphorylase support a preference for basic residue C-terminal to the 
phosphoserine for effective recognition and dephosphorylation of 
phosphorylase a by protein phosphatase-1. Additional mutants of 
phosphorylase a will help broaden our understanding of protein phosphatase-
1 specificity. 
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